<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/435552</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Bioinformatics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Interference with HIV infection of the first cell is essential for viral clearance in a pre-exposure prophylaxis model</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>De Las Muelas</surname><given-names>Ana Moyano</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lustig</surname><given-names>Gila</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rodel</surname><given-names>Hylton E.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Antal</surname><given-names>Tibor</given-names></name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8571-2004</contrib-id>
<name><surname>Sigal</surname><given-names>Alex</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Africa Health Research Institute</institution>, Durban, <country>South Africa</country>;</aff>
<aff id="a2"><label>2</label><institution>School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal</institution>, Durban, <country>South Africa</country>;</aff>
<aff id="a3"><label>3</label><institution>School of Mathematics, University of Edinburgh</institution>, Edinburgh, <country>UK</country>;</aff>
<aff id="a5"><label>5</label><institution>Max Planck Institute for Infection Biology</institution>, Berlin, <country>Germany</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>For correspondence: <email>Alex.Sigal@ahri.org</email> (AS)</corresp>
</author-notes>
<pub-date pub-type="epub"><year>2018</year></pub-date>
<elocation-id>435552</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>04</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="435552.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>Pre-exposure prophylaxis (PrEP) uses relatively weak HIV inhibition to reduce transmission between individuals. Why this approach is successful is unclear. Here we derive and experimentally validate a mathematical model for predicting infection clearance with PrEP based on the measured effect of a drug on the HIV replication ratio and number of initial infected cells. We tested the model by inhibiting low dose HIV infection with tenofovir, which reduces infection frequency per cell, and atazanavir, which reduces the cellular burst size of viable virions. Both drugs were at concentrations which allowed similar HIV replication. Reducing infection frequency dramatically increased infection clearance, while reducing burst size did not. This indicates that initial infection is vulnerable to inhibition before it infects the first cell, but not thereafter. Our model explains why PrEP is potent at drug concentrations which are ineffective against established infection, and provides a framework to test drug effectiveness for PrEP.</p>
</abstract>
<counts>
<page-count count="20"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Antiretroviral therapy (ART) currently used to treat ongoing HIV infection combines several potent antiretroviral drugs (ARVs). Yet, no current ART regimen has been successful in extinguishing infection once it is established in the human host (<xref rid="c20" ref-type="bibr"><italic>Churchill et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c67" ref-type="bibr"><italic>Sigal and Baltimore</italic> (<italic>2012</italic>)</xref>). In contrast to the robustness of HIV infection once established, initial HIV transmission between an infected and uninfected individual is more fragile. The probability for an exposed individual to become infected does not exceed 0.02 per sexual act under any set of conditions and is usually much lower (<xref rid="c36" ref-type="bibr"><italic>Gray et al.</italic> (<italic>2001</italic>)</xref>; <xref rid="c40" ref-type="bibr"><italic>Jin et al.</italic> (<italic>2010</italic>)</xref>). It generally involves one founder viral clone (<xref rid="c43" ref-type="bibr"><italic>Keele et al.</italic> (<italic>2008</italic>)</xref>). This indicates that an infection bottleneck exists, where most infection attempts by transmitted virions are unsuccessful.</p>
<p>The probability of initial transmission has been shown to be effectively reduced with a single ARV if the ARV is present before exposure takes place, an approach termed PrEP. The ARVs used for PrEP are a subset found in the full treatment regimen. A central agent is tenofovir (TFV), which interferes with viral reverse transcription and is usually delivered as the prodrug tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide fumarate (TAF TFV is either used by itself or co-administered with emtricitabine (FTC), another HIV reverse transcriptase inhibitor. This approach was shown to be effective in a non-human primate model of low dose infection, even when dosing was intermittent (<xref rid="c31" ref-type="bibr"><italic>Garc&#x00ED;a-Lerma et al.</italic> (<italic>2008</italic>)</xref>). In contrast to PrEP, TFV and FTC are only used in combination with a highly potent ARV such as dolutegravir or efavirenz to suppress established infection (<ext-link ext-link-type="uri" xlink:href="https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/11/what-to-start">https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/11/what-to-start</ext-link>).</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><p>Inhibition of established versus transmitted infection. Left panel shows established infection in an individual, where both the infected donor cell and uninfected target cell are exposed to antiretroviral drugs. In this case, a complete block of transmission is illustrated, with infection persisting in a reservoir of long lived infected cells. Right panel shows infection in PrEP, where the virus is produced in an infected individual where suppression of infection by drugs is absent or ineffective. The virus is then transmitted to an uninfected, PrEP treated individual. Two drug mechanisms of inhibition are shown: Reverse transcriptase inhibitors (RTI) and other ARVs such as integrase inhibitors reduce infection frequency by blocking HIV from becoming a provirus in the host DNA capable of making new infectious virions. Protease inhibitors (PI) reduce the burst size of infectious virions per infected cell by interfering with HIV maturation, a process which requires cleavage of HIV proteins by the HIV protease.</p></caption>
<graphic xlink:href="435552_fig1.tif"/>
</fig>
<p>The majority of clinical studies have shown PrEP effectiveness in a variety of populations, transmission modes, and drug delivery modalities (<xref rid="c11" ref-type="bibr"><italic>Baeten et al.</italic> (<italic>2012</italic>)</xref>; <xref rid="c17" ref-type="bibr"><italic>Choopanya et al.</italic> (<italic>2013</italic>)</xref>; <xref rid="c49" ref-type="bibr"><italic>McCormack et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c50" ref-type="bibr"><italic>Molina et al.</italic> (<italic>2015</italic>)</xref>; <xref rid="c74" ref-type="bibr"><italic>Thigpen et al.</italic> (<italic>2012</italic>)</xref>; <xref rid="c35" ref-type="bibr"><italic>Grant et al.</italic> (<italic>2010</italic>)</xref>; <xref rid="c42" ref-type="bibr"><italic>Karim et al.</italic> (<italic>2010</italic>)</xref>; <xref rid="c13" ref-type="bibr"><italic>Baeten et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c53" ref-type="bibr"><italic>Nel et al.</italic> (<italic>2016</italic>)</xref>). These include studies utilizing oral TDF alone (<xref rid="c11" ref-type="bibr"><italic>Baeten et al.</italic> (<italic>2012</italic>)</xref>; <xref rid="c17" ref-type="bibr"><italic>Choopanya et al.</italic> (<italic>2013</italic>)</xref>), oral TDF/FTC (<xref rid="c11" ref-type="bibr"><italic>Baeten et al.</italic> (<italic>2012</italic>)</xref>; <xref rid="c49" ref-type="bibr"><italic>McCormack et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c50" ref-type="bibr"><italic>Molina et al.</italic> (<italic>2015</italic>)</xref>; <xref rid="c74" ref-type="bibr"><italic>Thigpen et al.</italic> (<italic>2012</italic>)</xref>; <xref rid="c35" ref-type="bibr"><italic>Grant et al.</italic> (<italic>2010</italic>)</xref>), TFV gel (<xref rid="c42" ref-type="bibr"><italic>Karim et al.</italic> (<italic>2010</italic>)</xref>), and vaginal rings containing the reverse transcriptase inhibitor dapivirine (<xref rid="c13" ref-type="bibr"><italic>Baeten et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c53" ref-type="bibr"><italic>Nel et al.</italic> (<italic>2016</italic>)</xref>). Currently, PrEP is indicated when there is a high likelihood of HIV infection due to sexual contact with an HIV infected individual or injectable drug use (<xref rid="c79" ref-type="bibr"><italic>WHO</italic> (<italic>2015</italic>)</xref>; <xref rid="c6" ref-type="bibr"><italic>Anderson et al.</italic> (<italic>2012</italic>)</xref>) and may be used in conjunction with other prevention measures to reduce HIV incidence (<xref rid="c61" ref-type="bibr"><italic>Punyacharoensin et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c60" ref-type="bibr"><italic>Pretorius et al.</italic> (<italic>2010</italic>)</xref>). The reason to use a weakened ARV regimen is partly to decrease side effects and thus make it more acceptable to healthy individuals (<xref rid="c17" ref-type="bibr"><italic>Choopanya et al.</italic> (<italic>2013</italic>)</xref>; <xref rid="c45" ref-type="bibr"><italic>Koechlin et al.</italic> (<italic>2017</italic>)</xref>).</p>
<p>Why weak inhibition relative to the replicative capacity of HIV is effective in PrEP has not been investigated theoretically or experimentally, and such understanding may guide the development of new PrEP approaches. Currently approved ARVs include drugs which target various stages of the viral life cycle (<ext-link ext-link-type="uri" xlink:href="http://aidsinfo.nih.gov/">http://aidsinfo.nih.gov/</ext-link>). Among the most commonly used are inhibitors of the HIV proteins reverse transcriptase, integrase, and protease. Reverse transcriptase and integrase inhibitors prevent the initial infection of the cell but do not interfere with viral production from an already infected cell. Protease inhibitors do not interfere with cellular infection but reduce the number of viable virions an infected cell produces by interfering with virion maturation, which requires the HIV protease. Hence, the two mechanisms of inhibition involve either decreasing HIV infection frequency or viral burst size (<xref rid="c23" ref-type="bibr"><italic>Delbr&#x00FC;ck</italic> (<italic>1945</italic>)</xref>) per infected cell. However, it has been reported that protease inhibitors decrease infection frequency to some extent (<xref rid="c62" ref-type="bibr"><italic>Rabi et al.</italic> (<italic>2013</italic>)</xref>).</p>
<p>The effect of decreasing infection frequency or burst size should be symmetrical. The number of successful infections will be decreased if virions are prevented from infecting a cell by blocking their ability to become a provirus capable of generating new virions. It will also be decreased by reducing the output of new viable virions from an infected cell. In either case, fewer virions are available for the next cycle of infection (<xref rid="fig1" ref-type="fig">Figure 1</xref>, left panel). Whether or not infection expands is determined by the replication ratio <italic>R</italic><sub>0</sub>, which measures the mean number of new cells infected by a single infected cell. Given that <italic>R</italic><sub>0</sub> &#x003D; <italic>r&#x03BA;</italic>, where <italic>r</italic> is the probability of infection and <italic>&#x03BA;</italic> the viral burst size per cell (<xref rid="c63" ref-type="bibr"><italic>Ribeiro et al.</italic> (<italic>2010</italic>)</xref>; <xref rid="c55" ref-type="bibr"><italic>Nowak and May</italic> (<italic>2000</italic>)</xref>), decreasing <italic>R</italic><sub>0</sub> should be possible by either decreasing <italic>r</italic> or <italic>&#x03BA;</italic>. The exception to the symmetrical effects of the two drug mechanisms on HIV replication is when the virus originates at low numbers in a different individual. In this case, PrEP is applied to the yet uninfected, exposed individual. In HIV infection, if transmission is by cell-free virus (<xref rid="c39" ref-type="bibr"><italic>Jackson et al.</italic> (<italic>2018</italic>)</xref>; <xref rid="c15" ref-type="bibr"><italic>Boull&#x00E9; et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c68" ref-type="bibr"><italic>Sigal et al.</italic> (<italic>2011</italic>)</xref>; <xref rid="c44" ref-type="bibr"><italic>Kim et al.</italic> (<italic>2018</italic>)</xref>), using a drug which reduces burst size may not affect the incoming virus in the first infection cycle, since that virus is already mature (<xref rid="c9" ref-type="bibr"><italic>Arts and Hazuda</italic> (<italic>2012</italic>)</xref>). In contrast, a regimen which decreases infection frequency may be effective in preventing the incoming virus from infecting the first cell in the new host (<xref rid="fig1" ref-type="fig">Figure 1</xref>, right panel). After initial infection, both inhibitors should act symmetrically. Whether this difference between inhibitor mechanisms is important in determining the clearance probability &#x2013; the probability that infection will be terminated as a consequence of the inhibitor &#x2013; is unknown.</p>
<p>Here we modeled HIV infection as a function of the initial mean number of infected cells <italic>&#x03BB;</italic> and the replication ratio <italic>R</italic><sub>0</sub>, both of which we measured experimentally. We used two types of inhibition: reduction of infection frequency mediated by TFV, and reduction of the burst size of viable virions mediated by atazanavir (ATV), a drug belonging to the class of HIV protease inhibitors. We observed that while both drugs reduced <italic>R</italic><sub>0</sub> to a similar extent at the concentrations used, only TFV, which prevented successful infection of the first set of cells, was effective at clearing infection.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Derivation of a model for infection clearance</title>
<p>We first set out to model the effect of reducing infection frequency and burst size on the probability to clear infection (<italic>P</italic><sub><italic>c</italic></sub>). We model the infection chain of HIV transmissions between cells by using a branching process (<xref rid="c10" ref-type="bibr"><italic>Athreya et al.</italic> (<italic>2004</italic>)</xref>). We consider the initial stages of HIV infection, where host cells are not limiting in the number of cells that can be infected (<xref rid="c63" ref-type="bibr"><italic>Ribeiro et al.</italic> (<italic>2010</italic>)</xref>; <xref rid="c55" ref-type="bibr"><italic>Nowak and May</italic> (<italic>2000</italic>)</xref>). An infected cell produces a burst of <italic>&#x03BA;</italic> virions. <italic>&#x03BA;</italic> is on the order of 10<sup>3</sup> to 10<sup>4</sup> (<xref rid="c28" ref-type="bibr"><italic>Eckstein et al.</italic> (<italic>2001</italic>)</xref>; <xref rid="c16" ref-type="bibr"><italic>Chen et al.</italic> (<italic>2007</italic>)</xref>). The probability of one virion infecting the next cell is <italic>r</italic>, the infection frequency. We note the maximum number of cells which can be infected per burst is <italic>&#x03BA;</italic>. A key quantity is the product <italic>R</italic><sub>0</sub> &#x003D; <italic>r&#x00BA;</italic> (<xref rid="c55" ref-type="bibr"><italic>Nowak and May</italic> (<italic>2000</italic>)</xref>). <italic>R</italic><sub>0</sub> is approximately 10 <italic>in vivo</italic> (<xref rid="c63" ref-type="bibr"><italic>Ribeiro et al.</italic> (<italic>2010</italic>)</xref>). Eventual infection clearance is certain for <italic>R</italic><sub>0</sub> &#x2264; 1. For <italic>R</italic><sub>0</sub> &#x003E; 1, infection may still be cleared if, at any point in the infection chain, the number of infected cells is zero. Hence, we define the probability that infection is cleared as:
<disp-formula id="ueqn1"><alternatives><graphic xlink:href="435552_ueqn1.gif"/></alternatives></disp-formula>
where <italic>N</italic><sub><italic>i</italic></sub> is the number of infected cells in the <italic>i</italic>-th transmission step.</p>
<p>We denote by <italic>q</italic> the probability that infection starting from a single infected cell is cleared. In the biologically relevant case where <italic>&#x03BA;</italic> is large and <italic>r</italic> is small, with <italic>R</italic><sub>0</sub> finite, we can calculate <italic>q</italic> as (see derivation in Materials and Methods):
<disp-formula id="eqn1"><alternatives><graphic xlink:href="435552_eqn1.gif"/></alternatives></disp-formula></p>
<p>Here, <italic>W</italic> is the Lambert <italic>W</italic>&#x2013;function (<xref rid="c33" ref-type="bibr"><italic>Gradshteyn and Ryzhik</italic> (<italic>2014</italic>)</xref>), the inverse of the function <italic>g</italic>(<italic>x</italic>) &#x003D; <italic>xe</italic><sup><italic>x</italic></sup>.</p>
<p>As defined, <italic>q</italic> is the probability that the infection originating in a single infected cell will be cleared. We note that in the case where host cells are not limiting, as occurs in the initial stages of infection, infection chains originating from individual infected cells are independent of each other. Hence, given <italic>n</italic> initial infected cells,
<disp-formula id="eqn2"><alternatives><graphic xlink:href="435552_eqn2.gif"/></alternatives></disp-formula></p>
<p>We consider the initial number of infected cells as a random variable from a distribution <italic>&#x03D5;</italic><sub><italic>n</italic></sub>, where <italic>p</italic><sub><italic>c</italic></sub> &#x003D; &#x2211;<sub><italic>n</italic>&#x2265;0</sub> <italic>&#x03D5;</italic><sub><italic>n</italic></sub> <italic>q</italic><sup><italic>n</italic></sup>. A biologically relevant choice in viral infection is the Poisson distribution <italic>&#x03D5;</italic><sub><italic>n</italic></sub> &#x003D; <italic>&#x03BB;</italic><sup><italic>n</italic></sup> <italic>e</italic><sup>&#x2212;<italic>&#x03BB;</italic></sup>/ <italic>n</italic>&#x0021;, where <italic>&#x03BB;</italic> is the mean number of initial infected cells. Using <italic>e</italic><sup><italic>x</italic></sup> &#x003D; &#x2211;<sub><italic>n</italic>&#x2265;0</sub> <italic>x</italic><sup><italic>n</italic></sup>/ <italic>n</italic>&#x0021;, &#x2211;<sub><italic>n</italic>&#x2265;0</sub> <italic>&#x03D5;</italic><sub><italic>n</italic></sub> <italic>q</italic><sup><italic>n</italic></sup> then becomes:
<disp-formula id="eqn3"><alternatives><graphic xlink:href="435552_eqn3.gif"/></alternatives></disp-formula></p>
<p>We now consider the effect of the antiretroviral drug mechanism on <italic>&#x03BB;</italic> and <italic>q</italic>. We note that ARVs reduce either infection frequency <italic>r</italic> or burst size <italic>&#x03BA;</italic>. For drugs which reduce infection frequency, <italic>r</italic> &#x2192; <italic>d</italic><sub>1</sub><italic>r</italic>, and for drugs which reduce viral burst size, <italic>&#x03BA;</italic> &#x2192; <italic>d</italic><sub>2</sub><italic>&#x03BA;</italic>, where 0 &#x2264; <italic>d</italic><sub>1</sub>, <italic>d</italic><sub>2</sub> &#x2264; 1. Given <italic>R</italic><sub>0</sub> &#x003D; <italic>r&#x03BA;</italic> and therefore <italic>R</italic><sub>0</sub> &#x2192; <italic>R</italic><sub>0</sub><italic>d</italic><sub>1</sub><italic>d</italic><sub>2</sub>, the effects of the drug mechanisms are symmetrical on <italic>q</italic>:
<disp-formula id="eqn4"><alternatives><graphic xlink:href="435552_eqn4.gif"/></alternatives></disp-formula></p>
<p>Hence, if the drugs decrease <italic>R</italic><sub>0</sub> to a similar extent, their effect on <italic>q</italic> will also be similar. However, given an initial transmission with cell-free virus, only the drug mechanism that decreases infection frequency will reduce the mean initial number of infected cells <italic>&#x03BB;</italic>. The mechanism which reduces burst size will only affect the success of the next transmission cycle. Therefore, the probability to clear infection with ARVs becomes:
<disp-formula id="eqn5"><alternatives><graphic xlink:href="435552_eqn5.gif"/></alternatives></disp-formula></p>
<p>Here <italic>q</italic><sub><italic>drug</italic></sub> is determined by <xref ref-type="disp-formula" rid="eqn4">Eq. (4)</xref>. Given that <italic>&#x03BB;</italic> is expected to be small, on the order of one infected cell, the probability of clearance is expected to be very sensitive to the drug mechanism which reduces infection frequency (<italic>d</italic><sub>1</sub>), provided the effect of the drug is present when initial infec-tion takes place. The drug mechanism which reduces burst size (<italic>d</italic><sub>2</sub>) misses this initial intervention point.</p>
<p>To visualize the effects of decreasing <italic>R</italic><sub>0</sub> versus <italic>&#x03BB;</italic>, we plotted <xref ref-type="disp-formula" rid="eqn3">Eq. (3)</xref> for a range of parameter values (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). It can be observed that for <italic>R</italic><sub>0</sub> &#x2264; 1, infection terminates. At <italic>R</italic><sub>0</sub> &#x2A86; 1.5, infection is not strongly sensitive to the exact <italic>R</italic><sub>0</sub> value. However at all <italic>R</italic><sub>0</sub> &#x003E; 1 values, the probability of infection clearance is very sensitive to <italic>&#x03BB;</italic>, provided <italic>&#x03BB;</italic> is small. This sensitivity is greatly reduced when <italic>&#x03BB;</italic> &#x2A86; 2.</p>
<p>To examine the effects of drug mechanism, we plotted infection clearance according to <xref ref-type="disp-formula" rid="eqn5">Eq. (5)</xref> at two conditions of <italic>R</italic><sub>0</sub> and <italic>&#x03BB;</italic> relative to <italic>d</italic><sub>1</sub> and <italic>d</italic><sub>2</sub> (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). In the first condition, <italic>R</italic><sub>0</sub> was suZciently small to be decreased below 1 by the drugs in the inhibition range used, while <italic>&#x03BB;</italic> was large. In the second condition, <italic>R</italic><sub>0</sub> was large while <italic>&#x03BB;</italic> small. In the first condition, both drug mechanisms had a similar effect on infection clearance, and <italic>P</italic><sub><italic>c</italic></sub> &#x003D; 1 when the effect of either drug reduced <italic>R</italic><sub>0</sub> below 1. In the second condition, only <italic>d</italic><sub>1</sub>, which decreased infection frequency, substantially increased <italic>P</italic><sub><italic>c</italic></sub>. <italic>d</italic><sub>2</sub>, which acted on burst size, had no appreciable effect. We note that based on observations of <italic>R</italic><sub>0</sub> &#x2248; 10 <italic>in vivo</italic> (<xref rid="c63" ref-type="bibr"><italic>Ribeiro et al.</italic> (<italic>2010</italic>)</xref>) and a probability of clearance of at least 0.98 per exposure from an HIV positive partner in the absence of PrEP (<xref rid="c36" ref-type="bibr"><italic>Gray et al.</italic> (<italic>2001</italic>)</xref>; <xref rid="c40" ref-type="bibr"><italic>Jin et al.</italic> (<italic>2010</italic>)</xref>) which is suggestive of a small value for <italic>&#x03BB;</italic>, the second condition likely reflects the physiological situation.</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><p>Effects of the initial infected cell number <italic>&#x03BB;</italic> and replication ratio <italic>R</italic><sub>0</sub> on the probability of infection clearance <italic>P</italic><sub><italic>c</italic></sub>. (A) <italic>P</italic><sub><italic>c</italic></sub> according to <xref ref-type="disp-formula" rid="eqn3">Eq. (3)</xref> at different parameter values for <italic>&#x03BB;</italic> and <italic>R</italic><sub>0</sub>. (B) <italic>P</italic><sub><italic>c</italic></sub> according to <xref ref-type="disp-formula" rid="eqn5">Eq. (5)</xref> when a drug attenuating infection frequency (<italic>d</italic><sub>1</sub>) or burst size (<italic>d</italic><sub>2</sub>) acts on <italic>&#x03BB;</italic> and <italic>R</italic><sub>0</sub>. Top panel shows the case where <italic>R</italic><sub>0</sub>&#x003D;5, <italic>&#x03BB;</italic> &#x003D;20, while bottom panel shows the case where <italic>R</italic><sub>0</sub>.&#x003D;20, <italic>&#x03BB;</italic> &#x003D;2. X-axis is drug strength as 1/<italic>d</italic>, y-axis is <italic>P</italic><sub><italic>c</italic></sub></p></caption>
<graphic xlink:href="435552_fig2.tif"/>
</fig>
</sec>
<sec id="s2b">
<title>Experimental determination of the probability of infection clearance</title>
<p>We examined experimentally whether <xref ref-type="disp-formula" rid="eqn5">Eq. (5)</xref> predicts <italic>P</italic><sub><italic>c</italic></sub> for different drug mechanisms at a low number of initial infected cells, the likely <italic>in vivo</italic> condition for initial infection. We used the reverse transcriptase inhibitor TFV and the protease inhibitor ATV to inhibit infection initiating as cell-free HIV. We measured the effect of each drug on the initial number of infected cells <italic>&#x03BB;</italic> from cell-free infection and on <italic>R</italic><sub>0</sub> after the first infection cycle. For virus, we used HIV NL(AD8), an HIV strain with a CCR5 tropic envelope protein. CCR5 tropism has been shown to be the predominant transmitted form between individuals (<xref rid="c43" ref-type="bibr"><italic>Keele et al.</italic> (<italic>2008</italic>)</xref>). As target cells for infection, we used a clone of the RevCEM infection indicator cell line (<xref rid="c80" ref-type="bibr"><italic>Wu et al.</italic> (<italic>2007</italic>)</xref>) which we first subcloned to increase detection efficiency (<xref rid="c15" ref-type="bibr"><italic>Boull&#x00E9; et al.</italic> (<italic>2016</italic>)</xref>) then modified to express the CCR5 receptor (RevCEM-B8, Materials and Methods). Detection of infected cells was done by detecting the number of GFP positive cells using flow cytometry.</p>
<p>We titrated TFV and ATV to obtain a similar effect on ongoing viral replication, which occurred at 60 <italic>&#x03BC;</italic>M and 16 <italic>n</italic>M of TFV and ATV respectively. We then infected cells in the presence of these drug concentrations and measured infection over time to precisely measure <italic>R</italic><sub>0</sub> for each drug condition. We initiated infection with the same dose of cell-free HIV for each infection condition. After initiation of infection, ongoing infection was maintained by transmission through coculture of infected and uninfected cells. To maintain nutrients for cell growth and prevent the depletion of the uninfected target cell population, we passaged cells every two days by diluting infection with fresh medium at a 1:2 ratio for infection conditions with drug. Proliferation of uninfected cells was suZcient to maintain uninfected cell numbers, and infection was below 5 percent for both drug conditions at all time-points, ensuring target cells were not limiting (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). For the no drug condition, the infection expanded much more rapidly. Therefore, the infected cell culture was passaged by diluting the infected cells 1:100 every 2 days into uninfected cells. Infection was monitored over 8 days. Despite the use of the same HIV cell-free input dose, there were pronounced differences at day 2 between TFV and ATV (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). This time-point re2ects the results of the initial cell-free infection given an approximately 2 day viral cycle (<xref rid="c59" ref-type="bibr"><italic>Perelson et al.</italic> (<italic>1996</italic>)</xref>). Cell-free infection was strongly inhibited by TFV relative to no drug. In contrast, the effect of ATV on cell-free infection was much weaker. After the day 2 time-point, infection expanded with similar dynamics for both drug conditions, and much more rapidly when no drug was present.</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3.</label>
<caption><p>Experimental measurement of drug effect on <italic>R</italic><sub>0</sub> and the initial number of infected cells <italic>&#x03BB;</italic>. (A) Flow cytometry plots of the fraction of infected cells at different days post infection in the absence of drug or presence of 60 <italic>&#x03BC;</italic>M TFV or 16 <italic>n</italic>M ATV. Day 2 is the first time-point after the initial cell-free infection, corresponding to approximately one viral cycle. X-axis is GFP fluorescence, y-axis is autofluorescence, with the fraction of infected cells corresponding to the cells within the area outlined in yellow. Infected cell cultures in the presence of either drug were diluted 1:2 every 2 days. Infected cultures in the absence of drug were diluted 1:100 into uninfected cells every 2 days. (B) Measurement of <italic>R</italic><sub>0</sub> in the absence and presence of drug. The number of infected cells at each time-point is normalized by the number of infected cells at day 2 and corrected for the dilution factor used in each infection cycle. 3 independent experiment were performed, with each point denoting the mean &#x00B1; std of 3 experimental replicates per experiment. Infection in the absence of drug is shown as red circles, TFV as blue triangles, and ATV as green squares. (C) Effect of drug on <italic>&#x03BB;</italic>. For each drug condition <italic>&#x03BB;</italic> was measured 2 days after cell-free HIV infection and normalized by <italic>&#x03BB;</italic> for no drug. Mean &#x00B1; std of 3 independent experiments, where normalization was with <italic>&#x03BB;</italic> in the absence of drug as measured in the same experiment. Raw numbers of infected cells averaged over all experiments were 1.3<italic>x</italic>10<sup>4</sup> &#x00B1; 1.5<italic>x</italic>10<sup>3</sup> for no drug infection, 3.4<italic>x</italic>10<sup>2</sup> &#x00B1; 1.3<italic>x</italic>10<sup>2</sup> for TFV and 1.1<italic>&#x00D7;</italic>10<sup>4</sup> &#x00B1; 7.4<italic>x</italic>10<sup>3</sup> for ATV (mean &#x00B1; std).</p></caption>
<graphic xlink:href="435552_fig3.tif"/>
</fig>
<p>We plotted the total number of infected cells, corrected for cells removed during passaging, versus time (<xref rid="fig3" ref-type="fig">Figure 3B</xref>). We then calculated the effect of drug on <italic>R</italic><sub>0</sub> over a two day cycle (<xref ref-type="table" rid="tbl1">Table 1</xref>). <italic>R</italic><sub>0</sub> values were calculated as 4.2 &#x00B1; 0.73 for TFV and 3.2 &#x00B1; 0.088 for ATV (mean &#x00B1; std). <italic>R</italic><sub>0</sub> for infection in the absence was 143 &#x00B1; 15 in the cell line. We then measured the effect of the drugs on <italic>&#x03BB;</italic> after the first cycle of infection (day 0 to day 2), and compared the results to infection in the absence of drug. <italic>&#x03BB;</italic> in the presence of drug divided by <italic>&#x03BB;</italic> for the no drug condition (<italic>&#x03BB;</italic><sub><italic>norm</italic></sub>) was 0.027 &#x00B1; 0.014 for TFV and 0.88 &#x00B1; 0.16 for ATV, (<xref rid="fig3" ref-type="fig">Figure 3C</xref>, <xref ref-type="table" rid="tbl1">Table 1</xref>). The decrease in <italic>&#x03BB;</italic> for TFV versus ATV was signi1cant (p&#x003D;6<italic>x</italic>10<sup>&#x2212;14</sup>, t-test).</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><p>Measured Parameter Values</p></caption>
<graphic xlink:href="435552_tbl1.tif"/>
</table-wrap>
<p>We then set out to investigate whether TFV and ATV could increase the probability of clearance of low inoculum infection, corresponding to <italic>in vivo</italic> exposure. We used 6.3<italic>x</italic>10<sup>3</sup> viral copies (Materials and Methods), predicted to result in approximately 3 initial infected cells based on a regression of the number of infected cells versus input viral load (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). Infection was initiated with the same cell-free viral dose for all conditions, and infected cells were cultured for 8 days in the presence of drugs. Steady state cell viability was maintained by passaging the culture using a 1:2 dilution of cells into fresh medium with drug. After 8 days, drug was washed away and infection amplified by growth for 6 days in the absence of drug, with passaging every 2 days, to detect the presence of any infected cells after drug treatment. For the no drug infection condition, it was suZcient to culture infection for 6 days to obtain a robust signal in terms of infected cells. The background level of GFP signal was estimated from uninfected cells (Materials and Methods). After ampli1cation in the absence of drug for the TFV and ATV conditions, infection was either clearly visible or absent (<xref rid="fig4" ref-type="fig">Figure 4B</xref>).</p>
<p>We did not experimentally observe clearance of infection in the absence of drug. In the presence of TFV, clearance rose dramatically, with approximately three quarters of infections extinguished. In contrast, only a minor increase of infection clearance was observed with ATV (<xref rid="fig4" ref-type="fig">Figure 4C</xref>). Clearance with TFV was significantly higher relative to no drug and ATV, while ATV was not significantly different from no drug (<italic>p</italic> &#x003C; 10<sup>&#x2212;5</sup> and <italic>p</italic> &#x003D; 0.37, respectively, using bootstrap). Calculation of <inline-formula><alternatives><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="435552_inline1.gif"/></alternatives></inline-formula> based on <xref ref-type="disp-formula" rid="eqn5">Eq. (5)</xref> using the measured values for <italic>&#x03BB;</italic> and <italic>R</italic><sub>0</sub> for each drug condition showed a similar trend to the experimental values, with a higher clearance probability for each condition relative to the experimental results. Hence, <xref ref-type="disp-formula" rid="eqn5">Eq. (5)</xref> was able to predict the relative effectiveness of each drug to terminate infection in an <italic>in vitro</italic> model of PrEP.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4.</label>
<caption><p>Probability of infection clearance depends on drug mechanism. (A) Determination of <italic>&#x03BB;</italic>. The number of infected cells was measured using flow cytometry as a function of cell-free HIV RNA copies for four virus stock dilutions yielding a number of infected cells above the limit of detection after one infection cycle. Data was then fit using linear regression to determine the input viral dose for 3 infected cells. Mean &#x00B1; std of 5 independent experiments. Dotted line is limit of detection. Green arrow marks number of HIV RNA copies used in the experiments. (B) Representative flow cytometry plots after 8 days of infection with the input cell-free virus in the presence of of TFV or ATV and further 6 days amplification of the same infection in the absence of drug. Each plot represents one independently cultured replicate of the experiment. Uninfected samples are shown in the left column, and infection in the presence of TFV or ATV is shown in the middle and right column respectively. X-axis is GFP fluorescence, y-axis is autofluorescence. The fraction of infected cells corresponds to the cells within the area outlined in green or red, with green indicating background GFP signal level as determined from the uninfected samples, and red indicating above background signal. (C) <inline-formula><alternatives><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="435552_inline2.gif"/></alternatives></inline-formula> as predicted by <xref ref-type="disp-formula" rid="eqn5">Eq. (5)</xref> (gray bars) based on the measured drug effects on <italic>R</italic><sub>0</sub> and <italic>&#x03BB;</italic>, and as experimentally measured (red bars). Presence of infection was assayed in 26 (no drug) or 27 (TFV and ATV) cell-free virus infected cell cultures from 4 independent experiments. Observed <inline-formula><alternatives><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="435552_inline3.gif"/></alternatives></inline-formula> was significantly higher than <inline-formula><alternatives><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="435552_inline4.gif"/></alternatives></inline-formula> and <inline-formula><alternatives><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="435552_inline5.gif"/></alternatives></inline-formula> (<italic>p</italic> &#x003C; 10<sup>&#x2212;5</sup> by bootstrap). <inline-formula><alternatives><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="435552_inline6.gif"/></alternatives></inline-formula> and <inline-formula><alternatives><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="435552_inline7.gif"/></alternatives></inline-formula> were not significantly different (<italic>p</italic> &#x003D; 0.37 by bootstrap).</p></caption>
<graphic xlink:href="435552_fig4.tif"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>In this study we modeled and experimentally measured the clearance probability of initial HIV infection in the face of different inhibitor mechanisms: attenuation of infection frequency (TFV) or viral burst size from the infected cell (ATV). We chose drug concentrations where replication was reduced but not fully suppressed to investigate the effect of suboptimal HIV inhibition. Given that PrEP regimens seem to be more likely to be subject to variable adherence relative to treatment of established infection (<xref rid="c75" ref-type="bibr"><italic>Van Damme et al.</italic> (<italic>2012</italic>)</xref>; <xref rid="c48" ref-type="bibr"><italic>Marrazzo et al.</italic> (<italic>2015</italic>)</xref>; <xref rid="c11" ref-type="bibr"><italic>Baeten et al.</italic> (<italic>2012</italic>)</xref>; <xref rid="c17" ref-type="bibr"><italic>Choopanya et al.</italic> (<italic>2013</italic>)</xref>; <xref rid="c49" ref-type="bibr"><italic>McCormack et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c50" ref-type="bibr"><italic>Molina et al.</italic> (<italic>2015</italic>)</xref>; <xref rid="c34" ref-type="bibr"><italic>Grant et al.</italic> (<italic>2014</italic>)</xref>), sub-optimal inhibition is not only a function of the drug regimen but may be a feature of the approach This may make achieving <italic>R</italic><sub>0</sub> &#x2A85; 1 more difficult than with therapy for established infection. Under this set of conditions and in agreement with model predictions, only TFV, the inhibitor which was able to act before the first cell was infected, was able to increase the probability of HIV clearance. The prediction was based on two parameters which were readily measurable: <italic>&#x03BB;</italic> is measured in one infection cycle with cell-free virus. <italic>R</italic><sub>0</sub> is measured using multiple viral cycles, but consists of relatively simple passaging of infection to ensure that uninfected target cells are not limiting. Prediction does require the calculation of the the Lambert function. This can be done by a wide range of algebra capable programs (in this study we used Matlab).</p>
<p>We show that the current PrEP approach utilizing drugs which target infection frequency is in fact the correct choice. However, the quantitative model presented here has utility beyond giving a rationale for what is already done. For example, ARVs with longer half-lives such as the integrase inhibitor cabotegravir may become future treatment modalities both as ongoing therapy and for PrEP (<xref rid="c8" ref-type="bibr"><italic>Andrews and Heneine</italic> (<italic>2015</italic>)</xref>). However, longer half-lives also result in the drug levels reaching steady state slower, as the time to reach 50 percent of the steady state concentration is one half-life (<xref rid="c77" ref-type="bibr"><italic>Wagner</italic> (<italic>1975</italic>)</xref>). Therefore, in early exposures post-administration, level of inhibition or drugs with long half-lives may be lower for initial infection relative to drugs of the same class but with shorter half-lives. This may mean that the calculated <italic>P</italic><sub><italic>c</italic></sub> may be different even among drugs which inhibit infection frequency and have similar effects on <italic>R</italic><sub>0</sub>. In contrast, how fast a drug is able to act post-administration may have little effect in suppressing established infection. These considerations may also shape the effectiveness of future therapeutic approaches such as vaccines which require antigen based immune recognition: if <italic>R</italic><sub>0</sub> &#x003E; 1 with the intervention, clearance would be unlikely if the immune mechanism is not rapid enough to prevent the 1rst set of cells from being infected. Hence, under conditions where exposure may take place relatively rapidly post-PrEP dosing, the model presented here will be able to predict the relative PrEP utility of drugs of the same class at the level of cellular infection.</p>
<p>Factors in addition to drug effectiveness in inhibiting cellular infection may determine which drug or drug combination is used in PrEP. Among others, important considerations include drug side e ffects and interactions with other drugs (<xref rid="c35" ref-type="bibr"><italic>Grant et al.</italic> (<italic>2010</italic>)</xref>; <xref rid="c7" ref-type="bibr"><italic>Anderson et al.</italic> (<italic>2010</italic>)</xref>; <xref rid="c17" ref-type="bibr"><italic>Choopanya et al.</italic> (<italic>2013</italic>)</xref>; <xref rid="c45" ref-type="bibr"><italic>Koechlin et al.</italic> (<italic>2017</italic>)</xref>), penetration to the initial site of infection (<xref rid="c7" ref-type="bibr"><italic>Anderson et al.</italic> (<italic>2010</italic>)</xref>; <xref rid="c58" ref-type="bibr"><italic>Patterson et al.</italic> (<italic>2011</italic>)</xref>; <xref rid="c71" ref-type="bibr"><italic>Spinner et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c52" ref-type="bibr"><italic>Murnane et al.</italic> (<italic>2013</italic>)</xref>; <xref rid="c12" ref-type="bibr"><italic>Baeten et al.</italic> (<italic>2013</italic>)</xref>), convenient dosing (<xref rid="c35" ref-type="bibr"><italic>Grant et al.</italic> (<italic>2010</italic>)</xref>; <xref rid="c7" ref-type="bibr"><italic>Anderson et al.</italic> (<italic>2010</italic>)</xref>; <xref rid="c12" ref-type="bibr"><italic>Baeten et al.</italic> (<italic>2013</italic>)</xref>), cost effectiveness (<xref rid="c54" ref-type="bibr"><italic>Nichols et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c5" ref-type="bibr"><italic>Anderson and Cooper</italic> (<italic>2009</italic>)</xref>; <xref rid="c57" ref-type="bibr"><italic>Paltiel et al.</italic> (<italic>2009</italic>)</xref>; <xref rid="c24" ref-type="bibr"><italic>Desai et al.</italic> (<italic>2008</italic>)</xref>; <xref rid="c60" ref-type="bibr"><italic>Pretorius et al.</italic> (<italic>2010</italic>)</xref>; <xref rid="c38" ref-type="bibr"><italic>Hallett et al.</italic> (<italic>2011</italic>)</xref>; <xref rid="c32" ref-type="bibr"><italic>Gomez et al.</italic> (<italic>2012</italic>)</xref>), and consequences that the use of the drug in PrEP will have on the transmission of resistant viral strains (<xref rid="c73" ref-type="bibr"><italic>Supervie et al.</italic> (<italic>2010</italic></xref>, <xref ref-type="bibr" rid="c72">2011</xref>); <xref rid="c26" ref-type="bibr"><italic>Dolling et al.</italic> (<italic>2012</italic>)</xref>; <xref rid="c25" ref-type="bibr"><italic>Dimitrov et al.</italic> (<italic>2013</italic>)</xref>; <xref rid="c1" ref-type="bibr"><italic>Abbas et al.</italic> (<italic>2013</italic>)</xref>; <xref rid="c65" ref-type="bibr"><italic>Saenz and Bonhoeffer</italic> (<italic>2013</italic>)</xref>; <xref rid="c76" ref-type="bibr"><italic>Van De Vijver et al.</italic> (<italic>2013</italic>)</xref>; <xref rid="c56" ref-type="bibr"><italic>Okano and Blower</italic> (<italic>2013</italic>)</xref>). These additional factors need to be taken into account when designing a PrEP regimen.</p>
<p>The model output using the measured values for <italic>&#x03BB;</italic> and <italic>R</italic><sub>0</sub> resulted in predicted probabilities of infection clearance which were higher than the experimentally observed clearance frequencies for all conditions. We speculate that the reason is an underestimation of the input number of infected cells <italic>&#x03BB;</italic>. We measured <italic>&#x03BB;</italic> one viral cycle after cell-free infection. If GFP expression in an infected cell was below threshold of detection at that time, the cell would be missed in the assay yet still amplify infection. Despite this, the relative effectiveness of each drug mechanism was clearly predicted by the model. Factors <italic>in vivo</italic> which may result in deviation from model predictions include transmission by cell-to-cell spread (<xref rid="c68" ref-type="bibr"><italic>Sigal et al.</italic> (<italic>2011</italic>)</xref>; <xref rid="c15" ref-type="bibr"><italic>Boull&#x00E9; et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c39" ref-type="bibr"><italic>Jackson et al.</italic> (<italic>2018</italic>)</xref>; <xref rid="c41" ref-type="bibr"><italic>Jolly et al.</italic> (<italic>2004</italic>)</xref>; <xref rid="c27" ref-type="bibr"><italic>Duncan et al.</italic> (<italic>2014</italic>)</xref>; <xref rid="c4" ref-type="bibr"><italic>Agosto et al.</italic> (<italic>2015</italic></xref>, <xref ref-type="bibr" rid="c3">2018</xref>); <xref rid="c46" ref-type="bibr"><italic>Law et al.</italic> (<italic>2016</italic>)</xref>; <xref rid="c2" ref-type="bibr"><italic>Abela et al.</italic> (<italic>2012</italic>)</xref>; <xref rid="c64" ref-type="bibr"><italic>Rudnicka et al.</italic> (<italic>2009</italic>)</xref>; <xref rid="c66" ref-type="bibr"><italic>Sherer et al.</italic> (<italic>2007</italic>)</xref>; <xref rid="c81" ref-type="bibr"><italic>Zhong et al.</italic> (<italic>2013</italic>)</xref>; <xref rid="c22" ref-type="bibr"><italic>Del Portillo et al.</italic> (<italic>2011</italic>)</xref>; <xref rid="c70" ref-type="bibr"><italic>Sowinski et al.</italic> (<italic>2008</italic>)</xref>; <xref rid="c47" ref-type="bibr"><italic>Len et al.</italic> (<italic>2017</italic>)</xref>; <xref rid="c14" ref-type="bibr"><italic>Baxter et al.</italic> (<italic>2014</italic>)</xref>; <xref rid="c44" ref-type="bibr"><italic>Kim et al.</italic> (<italic>2018</italic>)</xref>). This should reduce the effectiveness of PrEP since the drugs would only act on <italic>R</italic><sub>0</sub> and not on <italic>&#x03BB;</italic>. A quantitative understanding such as presented here should detect deviations from the predictions made for cell-free infection, and thus allow a better understanding of any potential limits to PrEP.</p>
<p>HIV has been shown to rapidly seed a latent reservoir of infected cells (<xref rid="c18" ref-type="bibr"><italic>Chun et al.</italic> (<italic>1997</italic>a</xref>,<xref rid="c19" ref-type="bibr">b</xref>); <xref rid="c30" ref-type="bibr"><italic>Finzi et al.</italic> (<italic>1999</italic>)</xref>; <xref rid="c69" ref-type="bibr"><italic>Siliciano et al.</italic> (<italic>2003</italic>)</xref>; <xref rid="c29" ref-type="bibr"><italic>Eriksson et al.</italic> (<italic>2013</italic>)</xref>) which may also explain why it is necessary to block infection before the first cell is infected. However, at suboptimal inhibition, latent infection is not thought to play a role and infection is maintained by ongoing cycles of replication (<xref rid="c67" ref-type="bibr"><italic>Sigal and Baltimore</italic> (<italic>2012</italic>)</xref>). Evidence for this is the emergence of drug resistance with monotherapy (<xref rid="c21" ref-type="bibr"><italic>Deeks et al.</italic> (<italic>1997</italic>)</xref>; <xref rid="c51" ref-type="bibr"><italic>Molla et al.</italic> (<italic>1996</italic>)</xref>; <xref rid="c78" ref-type="bibr"><italic>Wei et al.</italic> (<italic>2002</italic>)</xref>). The current study provides a different rationale for why PrEP works best if the virus is inhibited before the first cellular infection, and enables a generalized evaluation of drugs to screen for the best candidates for this intervention.</p>
</sec>
<sec id="s4">
<title>Materials and methods</title>
<sec id="s4a">
<title>Inhibitors, viruses and cells</title>
<p>The following reagents were obtained through the AIDS Research and Reference Reagent Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health: the antiretroviral drugs ATV and TFV; RevCEM cells from Y. Wu and J. Marsh; HIV-1 NL4-3 CCR5 tropic infectious molecular clone (pNL(AD8)) from E. Freed; pBABE.CCR5, from N. Landau. Cell-free virus was produced by transfection of HEK293 cells with pNL(AD8) using TransIT-LT1 (Mirus) transfection reagent. Supernatant containing released virus was harvested two days post-transfection and filtered through a 0.45 micron filter (GVS). The number of HIV RNA genomes in viral stocks was determined using the RealTime HIV-1 viral load test (Abbott Diagnostics). The RevCEM HIV infection GFP indicator cell line was modified as follows for experiments with the CCR5 tropic virus: The E7 clone was generated from RevCEM cells as described in <xref rid="c15" ref-type="bibr"><italic>Boull&#x00E9; et al.</italic> (<italic>2016</italic>)</xref>. Briefly, the RevCEM cell line was sub-cloned by limiting dilution. Clones derived from single cells were expanded into duplicate 96-well plates, one optical and one standard tissue culture for continued growth. The optical plate was infected with NL4-3 and optical wells were scanned by microscopy to select clones with highest infection percentage by GFP expression. The clone E7 was selected based on &#x003E;70 percent GFP positive cells upon infection, expanded from the uninfected replicate plate and frozen. To generate the CCR5 expressing B8 reporter clone, RevCEM-E7 cells were infected with the pBABE.CCR5 retroviral vector which stably expressed CCR5 under the LTR promoter. Cells were sub-cloned by limiting dilution. Clones derived from single cells were expanded into duplicate 96-well plates, one optical and one standard tissue culture for continued growth. The optical plate was infected with pNL(AD8) and wells were scanned by microscopy to select clones which maintained similar GFP expression to the parental REVCEME7 clonal cell line. The clone RevCEM-B8 was selected based on &#x003E;70 percent GFP positive cells upon infection, expanded from the uninfected replicate plate, and frozen. Cell culture medium was complete RPMI 1640 supplemented with L-Glutamine, sodium pyruvate, HEPES, non-essential amino acids (Lonza), and 10 percent heat-inactivated FBS (Hyclone).</p>
</sec>
<sec id="s4b">
<title>Infection and flow cytometry</title>
<p>For determination of drug effect on <italic>R</italic><sub>0</sub> and <italic>&#x03BB;</italic>, cells were infected with 2.5<italic>x</italic>10<sup>7</sup> viral RNA copies in 2ml of cell culture containing 5<italic>x</italic>10<sup>5</sup> cells/ml. Every 2 days, the uninfected and drug treated cell cultures were passaged at a split ratio of 1:2, where half the cell culture was removed and fresh media with drug (for TFV and ATV) or without drug (for uninfected) was added. For the no drug infection condition, 1:100 of the culture (20 <italic>&#x03BC;</italic>l) was added to 2ml of fresh, uninfected cells at 5<italic>x</italic>10<sup>5</sup> cells/ml. The removed fraction of cells was used to detect infection as follows: The number of infected cells was acquired every 2 days using 3 measurements of 30 second acquisitions per sample (approximately 50,000 cells/sample) with a FACSCaliber machine (BD Biosciences) using the 488nm laser line. Flow rate on the machine was measured at each time-point, and acquisition time was multiplied by flow rate to obtain the number of infected cells per ml. For experiments measuring <inline-formula><alternatives><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="435552_inline8.gif"/></alternatives></inline-formula>, 200 <italic>&#x03BC;</italic>l of cells at a density of 5<italic>x</italic>10<sup>5</sup> cells/ml were infected with 6.3<italic>x</italic>10<sup>3</sup> viral RNA copies. For cell cultures with either no infection or containing ATV or TFV, passaging conditions were the same as for the experiments used to determine drug effect on <italic>R</italic><sub>0</sub> except that no culture was removed. Instead, new media with drug was added for the TFV and ATV conditions, and new media with no drug was added for the no infection condition. The infection volume therefore doubled every 2 days, and the cell culture was transferred to larger volume wells to preserve a constant surface to volume ratio. After 8 days (4 passages), cells were spun down, washed once in medium with no drug, and resuspended at 5<italic>x</italic>10<sup>5</sup> cells/ml in fresh medium with no drug. Cells were then further passaged in the absence of drug for 6 days (3 passages) using a 1:2 dilution every 2 days to amplify any infection in the culture. For infection in the absence of drug, cells were passaged for 6 days (3 passages) using a 1:2 dilution every 2 days with fresh medium without removing any of the cell culture. The number of infected cells was acquired at the end of the experiment (14 days post-infection for the uninfected, TFV and ATV conditions and 6 days for the no drug infection condition) as 30 second acquisitions per sample with a FACSCaliber machine as above. Results were analyzed using FlowJo 10.0.8 software. The background frequency of positive cells was determined by acquiring uninfected samples (n&#x003D;17 from 4 independent experiments). A sample was scored as infected if the number of GFP positive cells was greater than that in the highest background samples (4 positive cells per 30 second acquisition).</p>
</sec>
<sec id="s4c">
<title>Statistical significance by bootstrap</title>
<p>The vector of TFV results where infection was scored as either present (1) or absent (0) at each position in the vector, was resampled with replacement using 10<sup>5</sup> iterations to determine the number of iterations which resulted in a vector of 26 1&#x2019;s (no drug) or 26 of 27 1&#x2019;s (ATV).</p>
</sec>
<sec id="s4d">
<title>Derivation of the mathematical model</title>
<p>The probability that one cell with a burst of <italic>&#x03BA;</italic> virions will infect <italic>m</italic> cells and not infect <italic>&#x03BA;</italic> &#x2013; <italic>m</italic> cells is:
<disp-formula id="ueqn2"><alternatives><graphic xlink:href="435552_ueqn2.gif"/></alternatives></disp-formula>
where <italic>r</italic> id the infection probability per cell and <inline-formula><alternatives><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="435552_inline9.gif"/></alternatives></inline-formula>. We decline the generating function for this probability distribution:
<disp-formula id="ueqn3"><alternatives><graphic xlink:href="435552_ueqn3.gif"/></alternatives></disp-formula></p>
<p>Using the binomial formula <inline-formula><alternatives><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="435552_inline10.gif"/></alternatives></inline-formula>, we obtain
<disp-formula id="ueqn4"><alternatives><graphic xlink:href="435552_ueqn4.gif"/></alternatives></disp-formula></p>
<p>For <italic>R</italic> &#x003E; 1, the extinction probability of infection is given by the smallest root of <italic>p</italic>(<italic>s</italic>) &#x003D; <italic>s</italic> (<xref rid="c37" ref-type="bibr"><italic>Grimmett and Stirzaker</italic> (<italic>2001</italic>)</xref>), that is:
<disp-formula id="ueqn5"><alternatives><graphic xlink:href="435552_ueqn5.gif"/></alternatives></disp-formula></p>
<p>In the biologically relevant case where <italic>&#x03BA;</italic> is large and <italic>r</italic> is small, with <italic>R</italic><sub>0</sub> finite, we approximate the solution (<italic>rs</italic> &#x002B; 1 &#x2013; <italic>r</italic>)<sup><italic>&#x03BA;</italic></sup> &#x003D; <italic>e</italic><sup><italic>&#x03BA;</italic> ln(<italic>rs</italic>&#x002B;1&#x2013;<italic>r</italic>)</sup> &#x003D; <italic>e</italic><sup><italic>&#x03BA;</italic> ln(1&#x002B;<italic>r</italic>(<italic>s</italic>&#x2013;1))</sup> &#x2243; <italic>e</italic><sup><italic>&#x03BA;r</italic>(<italic>s</italic>&#x2013;1)</sup>. Therefore,
<disp-formula id="ueqn6"><alternatives><graphic xlink:href="435552_ueqn6.gif"/></alternatives></disp-formula></p>
<p>The solution for <italic>q</italic> to this equation is presented as <xref ref-type="disp-formula" rid="eqn1">Eq. (1)</xref>.</p>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>AS thanks Israel Michael Sigal for extensive discussions, and Deenan Pillay, Mark Siedner, and Brenda Tipper for comments on the manuscript.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><string-name><surname>Abbas</surname> <given-names>UL</given-names></string-name>, <string-name><surname>Glaubius</surname> <given-names>R</given-names></string-name>, <string-name><surname>Mubayi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hood</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mellors</surname> <given-names>JW</given-names></string-name>. <article-title>Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa</article-title>. <source>The Journal of infectious diseases</source>. <year>2013</year>; <volume>208</volume>(<issue>2</issue>):<fpage>224</fpage>&#x2013;<lpage>234</lpage>.</mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><string-name><surname>Abela</surname> <given-names>IA</given-names></string-name>, <string-name><surname>Berlinger</surname> <given-names>L</given-names></string-name>, <string-name><surname>Schanz</surname> <given-names>M</given-names></string-name>, <string-name><surname>Reynell</surname> <given-names>L</given-names></string-name>, <string-name><surname>G&#x00FC;nthard</surname> <given-names>HF</given-names></string-name>, <string-name><surname>Rusert</surname> <given-names>P</given-names></string-name>, <string-name><surname>Trkola</surname> <given-names>A</given-names></string-name>. <article-title>Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies</article-title>. <source>PLoS pathogens</source>. <year>2012</year>; <volume>8</volume>(<issue>4</issue>):<fpage>e1002634</fpage>.</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><string-name><surname>Agosto</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Herring</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Mothes</surname> <given-names>W</given-names></string-name>, <string-name><surname>Henderson</surname> <given-names>A J</given-names></string-name>. <article-title>HIV-1-Infected CD4&#x002B; T Cells Facilitate Latent Infection of Resting CD4&#x002B; T Cells through Cell-Cell Contact</article-title>. <source>Cell reports</source>. <year>2018</year>; <volume>24</volume>(<issue>8</issue>):<fpage>2088</fpage>&#x2013;<lpage>2100</lpage>.</mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><string-name><surname>Agosto</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Uchil</surname> <given-names>PD</given-names></string-name>, <string-name><surname>Mothes</surname> <given-names>W</given-names></string-name>. <article-title>HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy</article-title>. <source>Trends in microbiology</source>. <year>2015</year>; <volume>23</volume>(<issue>5</issue>):<fpage>289</fpage>&#x2013;<lpage>295</lpage>.</mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><string-name><surname>Anderson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cooper</surname> <given-names>D</given-names></string-name>. <article-title>cost-effectiveness of pre-exposure prophylaxis for Hiv in an Msm population: Bpd1/6</article-title>. <source>Hiv Medicine</source>. <year>2009</year>; <volume>10</volume>:<fpage>39</fpage>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><string-name><surname>Anderson</surname> <given-names>PL</given-names></string-name>, <string-name><surname>Glidden</surname> <given-names>DV</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Buchbinder</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lama</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Guanira</surname> <given-names>JV</given-names></string-name>, <string-name><surname>McMahan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Bushman</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Casap&#x00ED;a</surname> <given-names>M</given-names></string-name>, <string-name><surname>Montoya-Herrera</surname> <given-names>O</given-names></string-name>, <string-name><surname>Veloso</surname> <given-names>VG</given-names></string-name>, <string-name><surname>Mayer</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Chariyalertsak</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schechter</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bekker</surname> <given-names>LG</given-names></string-name>, <string-name><surname>Kall&#x00E1;s</surname> <given-names>EG</given-names></string-name>, <string-name><surname>Grant</surname> <given-names>RM</given-names></string-name>. <article-title>Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men</article-title>. <source>Science translational medicine</source>. <year>2012</year>; <volume>4</volume>(<issue>151</issue>):<fpage>151ra125</fpage>&#x2013;<lpage>151ra125</lpage>.</mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><string-name><surname>Anderson</surname> <given-names>PL</given-names></string-name>, <string-name><surname>Kiser</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Gardner</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Rower</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Meditz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Grant</surname> <given-names>RM</given-names></string-name>. <article-title>Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection</article-title>. <source>Journal of Antimicrobial Chemotherapy</source>. <year>2010</year>; <volume>66</volume>(<issue>2</issue>):<fpage>240</fpage>&#x2013;<lpage>250</lpage>.</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><string-name><surname>Andrews</surname> <given-names>CD</given-names></string-name>, <string-name><surname>Heneine</surname> <given-names>W</given-names></string-name>. <article-title>Cabotegravir long-acting for HIV-1 prevention</article-title>. <source>Current Opinion in HIV and AIDS</source>. <year>2015</year>; <volume>10</volume>(<issue>4</issue>):<fpage>258</fpage>&#x2013;<lpage>263</lpage>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><string-name><surname>Arts</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Hazuda</surname> <given-names>DJ</given-names></string-name>. <article-title>HIV-1 antiretroviral drug therapy</article-title>. <source>Cold Spring Harbor perspectives in medicine</source>. <year>2012</year>; <volume>2</volume>(<issue>4</issue>):<fpage>a007161</fpage>.</mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><string-name><surname>Athreya</surname> <given-names>KB</given-names></string-name>, <string-name><surname>Ney</surname> <given-names>PE</given-names></string-name>, <string-name><surname>Ney</surname> <given-names>P</given-names></string-name>. <article-title>Branching processes</article-title>. <source>Courier Corporation</source>; <year>2004</year>.</mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><string-name><surname>Baeten</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Donnell</surname> <given-names>D</given-names></string-name>, <string-name><surname>Ndase</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mugo</surname> <given-names>NR</given-names></string-name>, <string-name><surname>Campbell</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Wangisi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tappero</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Bukusi</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Katabira</surname> <given-names>E</given-names></string-name>, <string-name><surname>Ronald</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tumwesigye</surname> <given-names>E</given-names></string-name>, <string-name><surname>Were</surname> <given-names>E</given-names></string-name>, <string-name><surname>Fife</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Kiarie</surname> <given-names>J</given-names></string-name>, <string-name><surname>Farquhar</surname> <given-names>C</given-names></string-name>, <string-name><surname>John-Stewart</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kakia</surname> <given-names>A</given-names></string-name>, <string-name><surname>Odoyo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mucunguzi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Nakku-Joloba</surname> <given-names>E</given-names></string-name>, <string-name><surname>Twesigye</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ngure</surname> <given-names>K</given-names></string-name>, <string-name><surname>Apaka</surname> <given-names>C</given-names></string-name>, <string-name><surname>Tamooh</surname> <given-names>H</given-names></string-name>, <string-name><surname>Gabona</surname> <given-names>F</given-names></string-name>, <string-name><surname>Mujugira</surname> <given-names>A</given-names></string-name>, <string-name><surname>Panteleeff</surname> <given-names>D</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Kidoguchi</surname> <given-names>L</given-names></string-name>, <string-name><surname>Krows</surname> <given-names>M</given-names></string-name>, <string-name><surname>Revall</surname> <given-names>J</given-names></string-name>, <string-name><surname>Morrison</surname> <given-names>S</given-names></string-name>, <string-name><surname>Haugen</surname> <given-names>H</given-names></string-name>, <string-name><surname>Emmanuel-Ogier</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ondrejcek</surname> <given-names>L</given-names></string-name>, <string-name><surname>Coombs</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Frenkel</surname> <given-names>L</given-names></string-name>, <string-name><surname>Hendrix</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bumpus</surname> <given-names>NN</given-names></string-name>, <string-name><surname>Bangsberg</surname> <given-names>D</given-names></string-name>, <string-name><surname>Haberer</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Stevens</surname> <given-names>WS</given-names></string-name>, <string-name><surname>Lingappa</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Celum</surname> <given-names>C</given-names></string-name>. <article-title>Antiretroviral prophylaxis for HIV prevention in heterosexual men and women</article-title>. <source>New England Journal of Medicine</source>. <year>2012</year>; <volume>367</volume>(<issue>5</issue>):<fpage>399</fpage>&#x2013;<lpage>410</lpage>.</mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><string-name><surname>Baeten</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Haberer</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>AY</given-names></string-name>, <string-name><surname>Sista</surname> <given-names>N</given-names></string-name>. <article-title>Pre-exposure prophylaxis for HIV prevention: where have we been and where are we going?</article-title> <source>Journal of acquired immune defficiency syndromes (1999)</source>. <year>2013</year>; <volume>63</volume>(<issue>0 2</issue>):<fpage>S122</fpage>.</mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><string-name><surname>Baeten</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Palanee-Phillips</surname> <given-names>T</given-names></string-name>, <string-name><surname>Brown</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>K</given-names></string-name>, <string-name><surname>Soto-Torres</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Govender</surname> <given-names>V</given-names></string-name>, <string-name><surname>Mgodi</surname> <given-names>NM</given-names></string-name>, <string-name><surname>Matovu Kiweewa</surname> <given-names>F</given-names></string-name>, <string-name><surname>Nair</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mhlanga</surname> <given-names>F</given-names></string-name>, <string-name><surname>Siva</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bekker</surname> <given-names>LG</given-names></string-name>, <string-name><surname>Jeenarain</surname> <given-names>N</given-names></string-name>, <string-name><surname>Gaffoor</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Martinson</surname> <given-names>F</given-names></string-name>, <string-name><surname>Makanani</surname> <given-names>B</given-names></string-name>, <string-name><surname>Pather</surname> <given-names>A</given-names></string-name>, <string-name><surname>Naidoo</surname> <given-names>L</given-names></string-name>, <string-name><surname>Husnik</surname> <given-names>M</given-names></string-name>, <string-name><surname>Richardson</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Parikh</surname> <given-names>UM</given-names></string-name>, <string-name><surname>Mellors</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Marzinke</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Hendrix</surname> <given-names>CW</given-names></string-name>, <string-name><surname>van der Straten</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ramjee</surname> <given-names>G</given-names></string-name>, <string-name><surname>Chirenje</surname> <given-names>ZM</given-names></string-name>, <string-name><surname>Nakabiito</surname> <given-names>C</given-names></string-name>, <string-name><surname>Taha</surname> <given-names>TE</given-names></string-name>, <string-name><surname>Jones</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mayo</surname> <given-names>A</given-names></string-name>, <string-name><surname>Scheckter</surname> <given-names>R</given-names></string-name>, <string-name><surname>Berthiaume</surname> <given-names>J</given-names></string-name>, <string-name><surname>Livant</surname> <given-names>E</given-names></string-name>, <string-name><surname>Jacobson</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ndase</surname> <given-names>P</given-names></string-name>, <string-name><surname>White</surname> <given-names>R</given-names></string-name>, <string-name><surname>Patterson</surname> <given-names>K</given-names></string-name>, <string-name><surname>Germuga</surname> <given-names>D</given-names></string-name>, <string-name><surname>Galaska</surname> <given-names>B</given-names></string-name>, <string-name><surname>Bunge</surname> <given-names>K</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>D</given-names></string-name>, <string-name><surname>Szydlo</surname> <given-names>DW</given-names></string-name>, <string-name><surname>Montgomery</surname> <given-names>ET</given-names></string-name>, <string-name><surname>Mensch</surname> <given-names>BS</given-names></string-name>, <string-name><surname>Torjesen</surname> <given-names>K</given-names></string-name>, <string-name><surname>Grossman</surname> <given-names>CI</given-names></string-name>, <string-name><surname>Chakhtoura</surname> <given-names>N</given-names></string-name>, <string-name><surname>Nel</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rosenberg</surname> <given-names>Z</given-names></string-name>, <etal>et al.</etal> <article-title>Use of a vaginal ring containing dapivirine for HIV-1 prevention in women</article-title>. <source>New England Journal of Medicine</source>. <year>2016</year>; <volume>375</volume>(<issue>22</issue>):<fpage>2121</fpage>&#x2013;<lpage>2132</lpage>.</mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><string-name><surname>Baxter</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Russell</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Duncan</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Willberg</surname> <given-names>CB</given-names></string-name>, <string-name><surname>Pablos</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Finzi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kaufmann</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Ochsenbauer</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kappes</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Groot</surname> <given-names>F</given-names></string-name>, <string-name><surname>Sattentau</surname> <given-names>QJ</given-names></string-name>. <article-title>Macrophage infection via selective capture of HIV-1-infected CD4&#x002B; T cells</article-title>. <source>Cell host &#x0026; microbe</source>. <year>2014</year>; <volume>16</volume>(<issue>6</issue>):<fpage>711</fpage>&#x2013;<lpage>721</lpage>.</mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><string-name><surname>Boull&#x00E9;</surname> <given-names>M</given-names></string-name>, <string-name><surname>M&#x00FC;ller</surname> <given-names>TG</given-names></string-name>, <string-name><surname>D&#x00E4;hling</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ganga</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Jackson</surname> <given-names>L</given-names></string-name>, <string-name><surname>Mahamed</surname> <given-names>D</given-names></string-name>, <string-name><surname>Oom</surname> <given-names>L</given-names></string-name>, <string-name><surname>Lustig</surname> <given-names>G</given-names></string-name>, <string-name><surname>Neher</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Sigal</surname> <given-names>A</given-names></string-name>. <article-title>HIV cell-to-cell spread results in earlier onset of viral gene expression by multiple infections per cell</article-title>. <source>PLoS pathogens</source>. <year>2016</year>; <volume>12</volume>(<issue>11</issue>):<fpage>e1005964</fpage>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><string-name><surname>Chen</surname> <given-names>HY</given-names></string-name>, <string-name><surname>Di Mascio</surname> <given-names>M</given-names></string-name>, <string-name><surname>Perelson</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Ho</surname> <given-names>DD</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>L</given-names></string-name>. <article-title>Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques</article-title>. <source>Proceedings of the National Academy of Sciences</source>. <year>2007</year>; <volume>104</volume>(<issue>48</issue>):<fpage>19079</fpage>&#x2013;<lpage>19084</lpage>.</mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><string-name><surname>Choopanya</surname> <given-names>K</given-names></string-name>, <string-name><surname>Martin</surname> <given-names>M</given-names></string-name>, <string-name><surname>Suntharasamai</surname> <given-names>P</given-names></string-name>, <string-name><surname>Sangkum</surname> <given-names>U</given-names></string-name>, <string-name><surname>Mock</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Leethochawalit</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chiamwongpaet</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kitisin</surname> <given-names>P</given-names></string-name>, <string-name><surname>Natrujirote</surname> <given-names>P</given-names></string-name>, <string-name><surname>Kittimunkong</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chuachoowong</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gvetadze</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>McNicholl</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Paxton</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Curlin</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Hendrix</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Vanichseni</surname> <given-names>S</given-names></string-name>. <article-title>Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial</article-title>. <source>The Lancet</source>. <year>2013</year>; <volume>381</volume>(<issue>9883</issue>):<fpage>2083</fpage>&#x2013;<lpage>2090</lpage>.</mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><string-name><surname>Chun</surname> <given-names>TW</given-names></string-name>, <string-name><surname>Carruth</surname> <given-names>L</given-names></string-name>, <string-name><surname>Finzi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>X</given-names></string-name>, <string-name><surname>DiGiuseppe</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Taylor</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hermankova</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chadwick</surname> <given-names>K</given-names></string-name>, <string-name><surname>Margolick</surname> <given-names>J</given-names></string-name>, <string-name><surname>Quinn</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Kuo</surname> <given-names>YH</given-names></string-name>, <string-name><surname>Brookmeyer</surname> <given-names>R</given-names></string-name>, <string-name><surname>Zeiger</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Barditch-Crovo</surname> <given-names>P</given-names></string-name>, <string-name><surname>Siliciano</surname> <given-names>RF</given-names></string-name>. <article-title>Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection</article-title>. <source>Nature</source>. <year>1997</year>; <volume>387</volume>(<issue>6629</issue>):<fpage>183</fpage>&#x2013;<lpage>188</lpage>.</mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><string-name><surname>Chun</surname> <given-names>TW</given-names></string-name>, <string-name><surname>Stuyver</surname> <given-names>L</given-names></string-name>, <string-name><surname>Mizell</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Ehler</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Mican</surname> <given-names>JAM</given-names></string-name>, <string-name><surname>Baseler</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lloyd</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Nowak</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Fauci</surname> <given-names>AS</given-names></string-name>. <article-title>Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy</article-title>. <source>Proceedings of the National Academy of Sciences</source>. <year>1997</year>; <volume>94</volume>(<issue>24</issue>):<fpage>13193</fpage>&#x2013;<lpage>13197</lpage>.</mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><string-name><surname>Churchill</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Deeks</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Margolis</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Siliciano</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Swanstrom</surname> <given-names>R</given-names></string-name>. <article-title>HIV reservoirs: what, where and how to target them</article-title>. <source>Nature Reviews Microbiology</source>. <year>2016</year>; <volume>14</volume>(<issue>1</issue>):<fpage>55</fpage>.</mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><string-name><surname>Deeks</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>M</given-names></string-name>, <string-name><surname>Holodniy</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kahn</surname> <given-names>JO</given-names></string-name>. <article-title>HIV-1 protease inhibitors: a review for clinicians</article-title>. <source>Jama</source>. <year>1997</year>; <volume>277</volume>(<issue>2</issue>):<fpage>145</fpage>&#x2013;<lpage>153</lpage>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><string-name><surname>Del Portillo</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tripodi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Najfeld</surname> <given-names>V</given-names></string-name>, <string-name><surname>Wodarz</surname> <given-names>D</given-names></string-name>, <string-name><surname>Levy</surname> <given-names>DN</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>BK</given-names></string-name>. <article-title>Multiploid inheritance of HIV-1 during cell-to-cell infection</article-title>. <source>Journal of virology</source>. <year>2011</year>; p. <fpage>JVI</fpage>&#x2013;<lpage>00231</lpage>.</mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><string-name><surname>Delbr&#x00FC;ck</surname> <given-names>M</given-names></string-name>. <article-title>The burst size distribution in the growth of bacterial viruses (bacteriophages)</article-title>. <source>Journal of bacteriol-ogy</source>. <year>1945</year>; <volume>50</volume>(<issue>2</issue>):<fpage>131</fpage>.</mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><string-name><surname>Desai</surname> <given-names>K</given-names></string-name>, <string-name><surname>Sansom</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Ackers</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Stewart</surname> <given-names>SR</given-names></string-name>, <string-name><surname>Hall</surname> <given-names>HI</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Sanders</surname> <given-names>R</given-names></string-name>, <string-name><surname>Scotton</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Soorapanth</surname> <given-names>S</given-names></string-name>, <string-name><surname>Boily</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Garnett</surname> <given-names>GP</given-names></string-name>, <string-name><surname>McElroy</surname> <given-names>P</given-names></string-name>. <article-title>Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness</article-title>. <source>Aids</source>. <year>2008</year>; <volume>22</volume>(<issue>14</issue>):<fpage>1829</fpage>&#x2013;<lpage>1839</lpage>.</mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><string-name><surname>Dimitrov</surname> <given-names>D</given-names></string-name>, <string-name><surname>Boily</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Brown</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Hallett</surname> <given-names>TB</given-names></string-name>. <article-title>Analytic review of modeling studies of ARV based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness</article-title>. <source>PLoS One</source>. <year>2013</year>; <volume>8</volume>(<issue>11</issue>):<fpage>e80927</fpage>.</mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><string-name><surname>Dolling</surname> <given-names>D</given-names></string-name>, <string-name><surname>Phillips</surname> <given-names>A</given-names></string-name>, <string-name><surname>Delpech</surname> <given-names>V</given-names></string-name>, <string-name><surname>Pillay</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cane</surname> <given-names>P</given-names></string-name>, <string-name><surname>Crook</surname> <given-names>A</given-names></string-name>, <string-name><surname>Shepherd</surname> <given-names>J</given-names></string-name>, <string-name><surname>Fearnhill</surname> <given-names>E</given-names></string-name>, <string-name><surname>Hill</surname> <given-names>T</given-names></string-name>, <string-name><surname>Dunn</surname> <given-names>D</given-names></string-name>. <article-title>Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men</article-title>. <source>HIV medicine</source>. <year>2012</year>; <volume>13</volume>(<issue>5</issue>):<fpage>309</fpage>&#x2013;<lpage>314</lpage>.</mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><string-name><surname>Duncan</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Williams</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Schiffner</surname> <given-names>T</given-names></string-name>, <string-name><surname>G&#x00E4;rtner</surname> <given-names>K</given-names></string-name>, <string-name><surname>Ochsenbauer</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kappes</surname> <given-names>J</given-names></string-name>, <string-name><surname>Russell</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Frater</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sattentau</surname> <given-names>QJ</given-names></string-name>. <article-title>High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse</article-title>. <source>Journal of virology</source>. <year>2014</year>; <volume>88</volume>(<issue>4</issue>):<fpage>2025</fpage>&#x2013;<lpage>2034</lpage>.</mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><string-name><surname>Eckstein</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Penn</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Korin</surname> <given-names>YD</given-names></string-name>, <string-name><surname>Scripture-Adams</surname> <given-names>DD</given-names></string-name>, <string-name><surname>Zack</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Kreisberg</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Roederer</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sherman</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Chin</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Goldsmith</surname> <given-names>MA</given-names></string-name>. <article-title>HIV-1 actively replicates in naive CD4&#x002B; T cells residing within human lymphoid tissues</article-title>. <source>Immunity</source>. <year>2001</year>; <volume>15</volume>(<issue>4</issue>):<fpage>671</fpage>&#x2013;<lpage>682</lpage>.</mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><string-name><surname>Eriksson</surname> <given-names>S</given-names></string-name>, <string-name><surname>Graf</surname> <given-names>EH</given-names></string-name>, <string-name><surname>Dahl</surname> <given-names>V</given-names></string-name>, <string-name><surname>Strain</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Yukl</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Lysenko</surname> <given-names>ES</given-names></string-name>, <string-name><surname>Bosch</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Lai</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chioma</surname> <given-names>S</given-names></string-name>, <string-name><surname>Emad</surname> <given-names>F</given-names></string-name>, <string-name><surname>Abdel-Mohsen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hoh</surname> <given-names>R</given-names></string-name>, <string-name><surname>Hecht</surname> <given-names>F</given-names></string-name>, <string-name><surname>Hunt</surname> <given-names>P</given-names></string-name>, <string-name><surname>Somsouk</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>J</given-names></string-name>, <string-name><surname>Johnston</surname> <given-names>R</given-names></string-name>, <string-name><surname>Siliciano</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Richman</surname> <given-names>DD</given-names></string-name>, <string-name><surname>O&#x2019;Doherty</surname> <given-names>U</given-names></string-name>, <string-name><surname>Palmer</surname> <given-names>S</given-names></string-name>, <string-name><surname>Deeks</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Siliciano</surname> <given-names>JD</given-names></string-name>. <article-title>Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies</article-title>. <source>PLoS pathogens</source>. <year>2013</year>; <volume>9</volume>(<issue>2</issue>):<fpage>e1003174</fpage>.</mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><string-name><surname>Finzi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Blankson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Siliciano</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Margolick</surname> <given-names>JB</given-names></string-name>, <string-name><surname>Chadwick</surname> <given-names>K</given-names></string-name>, <string-name><surname>Pierson</surname> <given-names>T</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>K</given-names></string-name>, <string-name><surname>Lisziewicz</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lori</surname> <given-names>F</given-names></string-name>, <string-name><surname>Flexner</surname> <given-names>C</given-names></string-name>, <string-name><surname>Quinn</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Chaisson</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Rosenberg</surname> <given-names>E</given-names></string-name>, <string-name><surname>Walker</surname> <given-names>B</given-names></string-name>, <string-name><surname>Gange</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gallant</surname> <given-names>J</given-names></string-name>, <string-name><surname>Siliciano</surname> <given-names>RF</given-names></string-name>. <article-title>Latent infection of CD4&#x002B; T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy</article-title>. <source>Nature medicine</source>. <year>1999</year>; <volume>5</volume>(<issue>5</issue>):<fpage>512</fpage>.</mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><string-name><surname>Garc&#x00ED;a-Lerma</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Otten</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Qari</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Jackson</surname> <given-names>E</given-names></string-name>, <string-name><surname>Cong</surname> <given-names>Me</given-names></string-name>, <string-name><surname>Masciotra</surname> <given-names>S</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>W</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>C</given-names></string-name>, <string-name><surname>Adams</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Monsour</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lipscomb</surname> <given-names>J</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Delinsky</surname> <given-names>D</given-names></string-name>, <string-name><surname>Schinazi</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Janssen</surname> <given-names>R</given-names></string-name>, <string-name><surname>M Folks</surname> <given-names>T</given-names></string-name>, <string-name><surname>Heneine</surname> <given-names>W</given-names></string-name>. <article-title>Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir</article-title>. <source>PLoS medicine</source>. <year>2008</year>; <volume>5</volume>(<issue>2</issue>):<fpage>e28</fpage>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><string-name><surname>Gomez</surname> <given-names>GB</given-names></string-name>, <string-name><surname>Borquez</surname> <given-names>A</given-names></string-name>, <string-name><surname>Caceres</surname> <given-names>CF</given-names></string-name>, <string-name><surname>Segura</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Grant</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Garnett</surname> <given-names>GP</given-names></string-name>, <string-name><surname>Hallett</surname> <given-names>TB</given-names></string-name>. <article-title>The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study</article-title>. <source>PLoS medicine</source>. <year>2012</year>; <volume>9</volume>(<issue>10</issue>):<fpage>e1001323</fpage>.</mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="book"><string-name><surname>Gradshteyn</surname> <given-names>IS</given-names></string-name>, <string-name><surname>Ryzhik</surname> <given-names>IM</given-names></string-name>. <source>Table of integrals, series, and products</source>. <publisher-name>Academic press</publisher-name>; <year>2014</year>.</mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><string-name><surname>Grant</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>PL</given-names></string-name>, <string-name><surname>McMahan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Amico</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Mehrotra</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hosek</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mosquera</surname> <given-names>C</given-names></string-name>, <string-name><surname>Casapia</surname> <given-names>M</given-names></string-name>, <string-name><surname>Montoya</surname> <given-names>O</given-names></string-name>, <string-name><surname>Buchbinder</surname> <given-names>S</given-names></string-name>, <string-name><surname>Veloso</surname> <given-names>VG</given-names></string-name>, <string-name><surname>Mayer</surname> <given-names>K</given-names></string-name>, <string-name><surname>Chariyalertsak</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bekker</surname> <given-names>LG</given-names></string-name>, <string-name><surname>Kallas</surname> <given-names>EG</given-names></string-name>, <string-name><surname>Schechter</surname> <given-names>M</given-names></string-name>, <string-name><surname>Guanira</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bushman</surname> <given-names>L</given-names></string-name>, <string-name><surname>Burns</surname> <given-names>DN</given-names></string-name>, <string-name><surname>Rooney</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Glidden</surname> <given-names>DV</given-names></string-name>, <article-title>iPrEx study team. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study</article-title>. <source>The Lancet infectious diseases</source>. <year>2014</year>; <volume>14</volume>(<issue>9</issue>):<fpage>820</fpage>&#x2013;<lpage>829</lpage>.</mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><string-name><surname>Grant</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Lama</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>PL</given-names></string-name>, <string-name><surname>McMahan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>AY</given-names></string-name>, <string-name><surname>Vargas</surname> <given-names>L</given-names></string-name>, <string-name><surname>Goicochea</surname> <given-names>P</given-names></string-name>, <string-name><surname>Casap&#x00ED;a</surname> <given-names>M</given-names></string-name>, <string-name><surname>Guanira-Carranza</surname> <given-names>JV</given-names></string-name>, <string-name><surname>Ramirez-Cardich</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Montoya-Herrera</surname> <given-names>O</given-names></string-name>, <string-name><surname>Fern&#x00E1;ndez</surname> <given-names>T</given-names></string-name>, <string-name><surname>Veloso</surname> <given-names>VG</given-names></string-name>, <string-name><surname>Buchbinder</surname> <given-names>SP</given-names></string-name>, <string-name><surname>Chariyalertsak</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schechter</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bekker</surname> <given-names>LG</given-names></string-name>, <string-name><surname>Mayer</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Kall&#x00E1;s</surname> <given-names>EG</given-names></string-name>, <string-name><surname>Amico</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Mulligan</surname> <given-names>K</given-names></string-name>, <string-name><surname>Bushman</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Hance</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Ganoza</surname> <given-names>C</given-names></string-name>, <string-name><surname>Defechereux</surname> <given-names>P</given-names></string-name>, <string-name><surname>Postle</surname> <given-names>B</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>F</given-names></string-name>, <string-name><surname>McConnell</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rooney</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Jaffe</surname> <given-names>HS</given-names></string-name>, <string-name><surname>Martinez</surname> <given-names>AI</given-names></string-name>, <string-name><surname>Burns</surname> <given-names>DN</given-names></string-name>, <string-name><surname>Glidden</surname> <given-names>DV</given-names></string-name>. <article-title>Preexposure chemoprophylaxis for HIV prevention in men who have sex with men</article-title>. <source>New England Journal of Medicine</source>. <year>2010</year>; <volume>363</volume>(<issue>27</issue>):<fpage>2587</fpage>&#x2013;<lpage>2599</lpage>.</mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><string-name><surname>Gray</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Wawer</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Brookmeyer</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sewankambo</surname> <given-names>NK</given-names></string-name>, <string-name><surname>Serwadda</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wabwire-Mangen</surname> <given-names>F</given-names></string-name>, <string-name><surname>Lutalo</surname> <given-names>T</given-names></string-name>, <string-name><surname>Li</surname> <given-names>X</given-names></string-name>, <string-name><surname>Quinn</surname> <given-names>TC</given-names></string-name>. <article-title>Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda</article-title>. <source>The Lancet</source>. <year>2001</year>; <volume>357</volume>(<issue>9263</issue>):<fpage>1149</fpage>&#x2013;<lpage>1153</lpage>.</mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="book"><string-name><surname>Grimmett</surname> <given-names>G</given-names></string-name>, <string-name><surname>Stirzaker</surname> <given-names>D</given-names></string-name>. <source>Probability and random processes</source>. <publisher-name>Oxford university press</publisher-name>; <year>2001</year>.</mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><string-name><surname>Hallett</surname> <given-names>TB</given-names></string-name>, <string-name><surname>Baeten</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Heffron</surname> <given-names>R</given-names></string-name>, <string-name><surname>Barnabas</surname> <given-names>R</given-names></string-name>, <string-name><surname>De Bruyn</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cremin</surname> <given-names>&#x00CD;</given-names></string-name>, <string-name><surname>Delany</surname> <given-names>S</given-names></string-name>, <string-name><surname>Garnett</surname> <given-names>GP</given-names></string-name>, <string-name><surname>Gray</surname> <given-names>G</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>L</given-names></string-name>, <string-name><surname>McIntyre</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rees</surname> <given-names>H</given-names></string-name>, <string-name><surname>Celum</surname> <given-names>C</given-names></string-name>, <string-name><surname>Salomon</surname> <given-names>JA</given-names></string-name>. <article-title>Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study</article-title>. <source>PLoS medicine</source>. <year>2011</year>; <volume>8</volume>(<issue>11</issue>):<fpage>e1001123</fpage>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><string-name><surname>Jackson</surname> <given-names>L</given-names></string-name>, <string-name><surname>Hunter</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cele</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ferreira</surname> <given-names>IM</given-names></string-name>, <string-name><surname>Young</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Karim</surname> <given-names>F</given-names></string-name>, <string-name><surname>Madansein</surname> <given-names>R</given-names></string-name>, <string-name><surname>Dullabh</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>CY</given-names></string-name>, <string-name><surname>Buckels</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Ganga</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Khan</surname> <given-names>K</given-names></string-name>, <string-name><surname>Boulle</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lustig</surname> <given-names>G</given-names></string-name>, <string-name><surname>Neher</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Sigal</surname> <given-names>A</given-names></string-name>. <article-title>Incomplete inhibition of HIV infection results in more HIV infected lymph node cells by reducing cell death</article-title>. <source>eLife</source>. <year>2018</year>; <volume>7</volume>:<fpage>e30134</fpage>.</mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="book"><string-name><surname>Jin</surname> <given-names>F</given-names></string-name>, <string-name><surname>Jansson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Law</surname> <given-names>M</given-names></string-name>, <string-name><surname>Prestage</surname> <given-names>GP</given-names></string-name>, <string-name><surname>Zablotska</surname> <given-names>I</given-names></string-name>, <string-name><surname>Imrie</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Kippax</surname> <given-names>SC</given-names></string-name>, <string-name><surname>Kaldor</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Grulich</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Wilson</surname> <given-names>DP</given-names></string-name>. <source>Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART</source>. <publisher-name>AIDS</publisher-name> (<publisher-loc>London, England</publisher-loc>). <year>2010</year>; <volume>24</volume>(<issue>6</issue>):<fpage>907</fpage>.</mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><string-name><surname>Jolly</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kashefi</surname> <given-names>K</given-names></string-name>, <string-name><surname>Hollinshead</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sattentau</surname> <given-names>QJ</given-names></string-name>. <article-title>HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse</article-title>. <source>Journal of Experimental Medicine</source>. <year>2004</year>; <volume>199</volume>(<issue>2</issue>):<fpage>283</fpage>&#x2013;<lpage>293</lpage>.</mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><string-name><surname>Karim</surname> <given-names>QA</given-names></string-name>, <string-name><surname>Karim</surname> <given-names>SSA</given-names></string-name>, <string-name><surname>Frohlich</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Grobler</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Baxter</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mansoor</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Kharsany</surname> <given-names>AB</given-names></string-name>, <string-name><surname>Sibeko</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mlisana</surname> <given-names>KP</given-names></string-name>, <string-name><surname>Omar</surname> <given-names>Z</given-names></string-name>, <etal>et al.</etal> <article-title>Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women</article-title>. <source>science</source>. <year>2010</year>; p. <fpage>1193748</fpage>.</mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><string-name><surname>Keele</surname> <given-names>BF</given-names></string-name>, <string-name><surname>Giorgi</surname> <given-names>EE</given-names></string-name>, <string-name><surname>Salazar-Gonzalez</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Decker</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Pham</surname> <given-names>KT</given-names></string-name>, <string-name><surname>Salazar</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>C</given-names></string-name>, <string-name><surname>Grayson</surname> <given-names>T</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Li</surname> <given-names>H</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>X</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kirchherr</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>F</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Ping</surname> <given-names>LH</given-names></string-name>, <string-name><surname>Swanstrom</surname> <given-names>R</given-names></string-name>, <string-name><surname>Tomaras</surname> <given-names>GD</given-names></string-name>, <string-name><surname>Blattner</surname> <given-names>WA</given-names></string-name>, <string-name><surname>Goepfert</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Kilby</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Saag</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Delwart</surname> <given-names>EL</given-names></string-name>, <string-name><surname>Busch</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Monteflori</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Haynes</surname> <given-names>BF</given-names></string-name>, <string-name><surname>Gaschen</surname> <given-names>B</given-names></string-name>, <string-name><surname>Athreya</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>HY</given-names></string-name>, <string-name><surname>Wood</surname> <given-names>N</given-names></string-name>, <string-name><surname>Seoighe</surname> <given-names>C</given-names></string-name>, <string-name><surname>Perelson</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Bhattacharya</surname> <given-names>T</given-names></string-name>, <string-name><surname>Korber</surname> <given-names>BT</given-names></string-name>, <string-name><surname>Hahn</surname> <given-names>BH</given-names></string-name>, <string-name><surname>Shaw</surname> <given-names>GM</given-names></string-name>. <article-title>Identi1cation and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection</article-title>. <source>Proceedingsof the National Academy of Sciences</source>. <year>2008</year>; <volume>105</volume>(<issue>21</issue>):<fpage>7552</fpage>&#x2013;<lpage>7557</lpage>.</mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><string-name><surname>Kim</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Chang</surname> <given-names>E</given-names></string-name>, <string-name><surname>Sigal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Baltimore</surname> <given-names>D</given-names></string-name>. <article-title>Dendritic cells eZciently transmit HIV to T Cells in a tenofovir and raltegravir insensitive manner</article-title>. <source>PloS one</source>. <year>2018</year>; <volume>13</volume>(<issue>1</issue>):<fpage>e0189945</fpage>.</mixed-citation></ref>
<ref id="c45"><mixed-citation publication-type="journal"><string-name><surname>Koechlin</surname> <given-names>FM</given-names></string-name>, <string-name><surname>Fonner</surname> <given-names>VA</given-names></string-name>, <string-name><surname>Dalglish</surname> <given-names>SL</given-names></string-name>, <string-name><surname>OReilly</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Baggaley</surname> <given-names>R</given-names></string-name>, <string-name><surname>Grant</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Rodolph</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hodges-Mameletzis</surname> <given-names>I</given-names></string-name>, <string-name><surname>Kennedy</surname> <given-names>CE</given-names></string-name>. <article-title>Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature</article-title>. <source>AIDS and Behavior</source>. <year>2017</year>; <volume>21</volume>(<issue>5</issue>):<fpage>1325</fpage>&#x2013;<lpage>1335</lpage>.</mixed-citation></ref>
<ref id="c46"><mixed-citation publication-type="journal"><string-name><surname>Law</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Komarova</surname> <given-names>NL</given-names></string-name>, <string-name><surname>Yewdall</surname> <given-names>AW</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>RK</given-names></string-name>, <string-name><surname>Herrera</surname> <given-names>OL</given-names></string-name>, <string-name><surname>Wodarz</surname> <given-names>D</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>BK</given-names></string-name>. <article-title>In vivo HIV-1 cell-to-cell transmission promotes multicopy micro-compartmentalized infection</article-title>. <source>Cell reports</source>. <year>2016</year>; <volume>15</volume>(<issue>12</issue>):<fpage>2771</fpage>&#x2013;<lpage>2783</lpage>.</mixed-citation></ref>
<ref id="c47"><mixed-citation publication-type="journal"><string-name><surname>Len</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Starling</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shivkumar</surname> <given-names>M</given-names></string-name>, <string-name><surname>Jolly</surname> <given-names>C</given-names></string-name>. <article-title>HIV-1 activates T cell signaling independently of antigen to drive viral spread</article-title>. <source>Cell reports</source>. <year>2017</year>; <volume>18</volume>(<issue>4</issue>):<fpage>1062</fpage>&#x2013;<lpage>1074</lpage>.</mixed-citation></ref>
<ref id="c48"><mixed-citation publication-type="journal"><string-name><surname>Marrazzo</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Ramjee</surname> <given-names>G</given-names></string-name>, <string-name><surname>Richardson</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Gomez</surname> <given-names>K</given-names></string-name>, <string-name><surname>Mgodi</surname> <given-names>N</given-names></string-name>, <string-name><surname>Nair</surname> <given-names>G</given-names></string-name>, <string-name><surname>Palanee</surname> <given-names>T</given-names></string-name>, <string-name><surname>Nakabiito</surname> <given-names>C</given-names></string-name>, <string-name><surname>Van Der Straten</surname> <given-names>A</given-names></string-name>, <string-name><surname>Noguchi</surname> <given-names>L</given-names></string-name>, <string-name><surname>Hendrix</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Dai</surname> <given-names>JY</given-names></string-name>, <string-name><surname>Ganesh</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mkhize</surname> <given-names>B</given-names></string-name>, <string-name><surname>Taljaard</surname> <given-names>M</given-names></string-name>, <string-name><surname>Parikh</surname> <given-names>UM</given-names></string-name>, <string-name><surname>Piper</surname> <given-names>J</given-names></string-name>, <string-name><surname>Masse</surname> <given-names>B</given-names></string-name>, <string-name><surname>Grossman</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rooney</surname> <given-names>J</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Watts</surname> <given-names>H</given-names></string-name>, <string-name><surname>Marzinke</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Hillier</surname> <given-names>SL</given-names></string-name>, <string-name><surname>McGowan</surname> <given-names>IM</given-names></string-name>, <string-name><surname>Chirenje</surname> <given-names>ZM</given-names></string-name>, <string-name><surname>Team</surname> <given-names>VS</given-names></string-name>. <article-title>Tenofovir-based preexposure prophylaxis for HIV infection among African women</article-title>. <source>New England Journal of Medicine</source>. <year>2015</year>; <volume>372</volume>(<issue>6</issue>):<fpage>509</fpage>&#x2013;<lpage>518</lpage>.</mixed-citation></ref>
<ref id="c49"><mixed-citation publication-type="journal"><string-name><surname>McCormack</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dunn</surname> <given-names>DT</given-names></string-name>, <string-name><surname>Desai</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dolling</surname> <given-names>DI</given-names></string-name>, <string-name><surname>Gafos</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gilson</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sullivan</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Clarke</surname> <given-names>A</given-names></string-name>, <string-name><surname>Reeves</surname> <given-names>I</given-names></string-name>, <string-name><surname>Schembri</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mackie</surname> <given-names>N</given-names></string-name>, <string-name><surname>Bowman</surname> <given-names>C</given-names></string-name>, <string-name><surname>Lacey</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Apea</surname> <given-names>V</given-names></string-name>, <string-name><surname>Brady</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fox</surname> <given-names>J</given-names></string-name>, <string-name><surname>Taylor</surname> <given-names>S</given-names></string-name>, <string-name><surname>Antonucci</surname> <given-names>S</given-names></string-name>, <string-name><surname>Khoo</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Rooney</surname> <given-names>J</given-names></string-name>, <string-name><surname>Nardone</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fisher</surname> <given-names>M</given-names></string-name>, <string-name><surname>McOwan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Phillips</surname> <given-names>AN</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Gazzard</surname> <given-names>B</given-names></string-name>, <string-name><surname>Gill</surname> <given-names>ON</given-names></string-name>. <article-title>Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial</article-title>. <source>The Lancet</source>. <year>2016</year>; <volume>387</volume>(<issue>10013</issue>):<fpage>53</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation></ref>
<ref id="c50"><mixed-citation publication-type="journal"><string-name><surname>Molina</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Capitant</surname> <given-names>C</given-names></string-name>, <string-name><surname>Spire</surname> <given-names>B</given-names></string-name>, <string-name><surname>Pialoux</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cotte</surname> <given-names>L</given-names></string-name>, <string-name><surname>Charreau</surname> <given-names>I</given-names></string-name>, <string-name><surname>Tremblay</surname> <given-names>C</given-names></string-name>, <string-name><surname>Le Gall</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Cua</surname> <given-names>E</given-names></string-name>, <string-name><surname>Pasquet</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>On-demand preexposure prophylaxis in men at high risk for HIV-1 infection</article-title>. <source>New England Journal of Medicine</source>. <year>2015</year>; <volume>373</volume>(<issue>23</issue>):<fpage>2237</fpage>&#x2013;<lpage>2246</lpage>.</mixed-citation></ref>
<ref id="c51"><mixed-citation publication-type="journal"><string-name><surname>Molla</surname> <given-names>A</given-names></string-name>, <string-name><surname>Korneyeva</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Vasavanonda</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schipper</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Mo</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Markowitz</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chernyavskiy</surname> <given-names>T</given-names></string-name>, <string-name><surname>Niu</surname> <given-names>P</given-names></string-name>, <string-name><surname>Lyons</surname> <given-names>N</given-names></string-name>, <string-name><surname>Hsu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Granneman</surname> <given-names>GR</given-names></string-name>, <string-name><surname>Ho</surname> <given-names>DD</given-names></string-name>, <string-name><surname>Boucher</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Leonard</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Norbeck</surname> <given-names>DW</given-names></string-name>, <string-name><surname>Kempf</surname> <given-names>DJ</given-names></string-name>. <article-title>Ordered accumulation of mutations in HIV protease confers resistance to ritonavir</article-title>. <source>Nature medicine</source>. <year>1996</year>; <volume>2</volume>(<issue>7</issue>):<fpage>760</fpage>&#x2013;<lpage>766</lpage>.</mixed-citation></ref>
<ref id="c52"><mixed-citation publication-type="book"><string-name><surname>Murnane</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Celum</surname> <given-names>C</given-names></string-name>, <string-name><surname>Nelly</surname> <given-names>M</given-names></string-name>, <string-name><surname>Campbell</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Donnell</surname> <given-names>D</given-names></string-name>, <string-name><surname>Bukusi</surname> <given-names>E</given-names></string-name>, <string-name><surname>Mujugira</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tappero</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kahle</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Baeten</surname> <given-names>JM</given-names></string-name>. <source>Efficacy of pre-exposure prophylaxis for HIV-1 prevention among high risk heterosexuals: subgroup analyses from the Partners PrEP Study</source>. <publisher-name>AIDS</publisher-name> (<publisher-loc>London, England</publisher-loc>). <year>2013</year>; <volume>27</volume>(<issue>13</issue>).</mixed-citation></ref>
<ref id="c53"><mixed-citation publication-type="journal"><string-name><surname>Nel</surname> <given-names>A</given-names></string-name>, <string-name><surname>van Niekerk</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kapiga</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bekker</surname> <given-names>LG</given-names></string-name>, <string-name><surname>Gama</surname> <given-names>C</given-names></string-name>, <string-name><surname>Gill</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kamali</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kotze</surname> <given-names>P</given-names></string-name>, <string-name><surname>Louw</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mabude</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Miti</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kusemererwa</surname> <given-names>S</given-names></string-name>, <string-name><surname>Tempelman</surname> <given-names>H</given-names></string-name>, <string-name><surname>Carstens</surname> <given-names>H</given-names></string-name>, <string-name><surname>Devlin</surname> <given-names>B</given-names></string-name>, <string-name><surname>Isaacs</surname> <given-names>M</given-names></string-name>, <string-name><surname>Malherbe</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mans</surname> <given-names>W</given-names></string-name>, <string-name><surname>Nuttall</surname> <given-names>J</given-names></string-name>, <string-name><surname>Russell</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ntshele</surname> <given-names>S</given-names></string-name>, <string-name><surname>Smit</surname> <given-names>M</given-names></string-name>, <string-name><surname>Solai</surname> <given-names>L</given-names></string-name>, <string-name><surname>Spence</surname> <given-names>P</given-names></string-name>, <string-name><surname>Steytler</surname> <given-names>J</given-names></string-name>, <string-name><surname>Windle</surname> <given-names>K</given-names></string-name>, <string-name><surname>Borremans</surname> <given-names>M</given-names></string-name>, <string-name><surname>Resseler</surname> <given-names>S</given-names></string-name>, <string-name><surname>Van Roey</surname> <given-names>J</given-names></string-name>, <string-name><surname>Parys</surname> <given-names>W</given-names></string-name>, <string-name><surname>Vangeneugden</surname> <given-names>T</given-names></string-name>, <string-name><surname>Van Baelen</surname> <given-names>B</given-names></string-name>, <string-name><surname>Rosenberg</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Team</surname> <given-names>RS</given-names></string-name>. <article-title>Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women</article-title>. <source>New England Journal of Medicine</source>. <year>2016</year>; <volume>375</volume>(<issue>22</issue>):<fpage>2133</fpage>&#x2013;<lpage>2143</lpage>.</mixed-citation></ref>
<ref id="c54"><mixed-citation publication-type="journal"><string-name><surname>Nichols</surname> <given-names>BE</given-names></string-name>, <string-name><surname>Boucher</surname> <given-names>CA</given-names></string-name>, <string-name><surname>van der Valk</surname> <given-names>M</given-names></string-name>, <string-name><surname>Rijnders</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>van de Vijver</surname> <given-names>DA</given-names></string-name>. <article-title>Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study</article-title>. <source>The Lancet Infectious Diseases</source>. <year>2016</year>; <volume>16</volume>(<issue>12</issue>):<fpage>1423</fpage>&#x2013;<lpage>1429</lpage>.</mixed-citation></ref>
<ref id="c55"><mixed-citation publication-type="book"><string-name><surname>Nowak</surname> <given-names>M</given-names></string-name>, <string-name><surname>May</surname> <given-names>RM</given-names></string-name>. <source>Virus dynamics: mathematical principles of immunology and virology: mathematical principles of immunology and virology</source>. <publisher-name>Oxford University Press</publisher-name>, <publisher-loc>UK</publisher-loc>; <year>2000</year>.</mixed-citation></ref>
<ref id="c56"><mixed-citation publication-type="journal"><string-name><surname>Okano</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Blower</surname> <given-names>S</given-names></string-name>. <article-title>HIV treatment, preexposure prophylaxis, and drug resistance: reconciling conflicting predictions from mathematical models</article-title>. <source>The Journal of infectious diseases</source>. <year>2013</year>; <volume>209</volume>(<issue>1</issue>):<fpage>163</fpage>&#x2013;<lpage>164</lpage>.</mixed-citation></ref>
<ref id="c57"><mixed-citation publication-type="journal"><string-name><surname>Paltiel</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Freedberg</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Scott</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Schackman</surname> <given-names>BR</given-names></string-name>, <string-name><surname>Losina</surname> <given-names>E</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>B</given-names></string-name>, <string-name><surname>Seage</surname> <given-names>GR</given-names></string-name>, <string-name><surname>Sloan</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Sax</surname> <given-names>PE</given-names></string-name>, <string-name><surname>Walensky</surname> <given-names>RP</given-names></string-name>. <article-title>HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness</article-title>. <source>Clinical Infectious Diseases</source>. <year>2009</year>; <volume>48</volume>(<issue>6</issue>):<fpage>806</fpage>&#x2013;<lpage>815</lpage>.</mixed-citation></ref>
<ref id="c58"><mixed-citation publication-type="journal"><string-name><surname>Patterson</surname> <given-names>KB</given-names></string-name>, <string-name><surname>Prince</surname> <given-names>HA</given-names></string-name>, <string-name><surname>Kraft</surname> <given-names>E</given-names></string-name>, <string-name><surname>Jenkins</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Shaheen</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Rooney</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Kashuba</surname> <given-names>AD</given-names></string-name>. <article-title>Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission</article-title>. <source>Science translational medicine</source>. <year>2011</year>; <volume>3</volume>(<issue>112</issue>):<fpage>112re4</fpage>&#x2013;<lpage>112re4</lpage>.</mixed-citation></ref>
<ref id="c59"><mixed-citation publication-type="journal"><string-name><surname>Perelson</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Neumann</surname> <given-names>AU</given-names></string-name>, <string-name><surname>Markowitz</surname> <given-names>M</given-names></string-name>, <string-name><surname>Leonard</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Ho</surname> <given-names>DD</given-names></string-name>. <article-title>HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time</article-title>. <source>Science</source>. <year>1996</year>; <volume>271</volume>(<issue>5255</issue>):<fpage>1582</fpage>&#x2013;<lpage>1586</lpage>.</mixed-citation></ref>
<ref id="c60"><mixed-citation publication-type="journal"><string-name><surname>Pretorius</surname> <given-names>C</given-names></string-name>, <string-name><surname>Stover</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bollinger</surname> <given-names>L</given-names></string-name>, <string-name><surname>Baca&#x00EB;r</surname> <given-names>N</given-names></string-name>, <string-name><surname>Williams</surname> <given-names>B</given-names></string-name>. <article-title>Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa</article-title>. <source>PloS one</source>. <year>2010</year>; <volume>5</volume>(<issue>11</issue>):<fpage>e13646</fpage>.</mixed-citation></ref>
<ref id="c61"><mixed-citation publication-type="journal"><string-name><surname>Punyacharoensin</surname> <given-names>N</given-names></string-name>, <string-name><surname>John Edmunds</surname> <given-names>W</given-names></string-name>, <string-name><surname>Angelis</surname> <given-names>D</given-names></string-name>, <string-name><surname>Delpech</surname> <given-names>V</given-names></string-name>, <string-name><surname>Hart</surname> <given-names>G</given-names></string-name>, <string-name><surname>Elford</surname> <given-names>J</given-names></string-name>, <string-name><surname>Brown</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gill</surname> <given-names>O</given-names></string-name>, <string-name><surname>White</surname> <given-names>R</given-names></string-name>. <article-title>Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK</article-title>: <source>A mathematical modelling study</source>. &#x002D; <year>2016</year> <volume>01</volume>; <fpage>3</fpage>.</mixed-citation></ref>
<ref id="c62"><mixed-citation publication-type="journal"><string-name><surname>Rabi</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Laird</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Durand</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Laskey</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shan</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bailey</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Chioma</surname> <given-names>S</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Siliciano</surname> <given-names>RF</given-names></string-name>. <article-title>Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance</article-title>. <source>The Journal of clinical investigation</source>. <year>2013</year>; <volume>123</volume>(<issue>9</issue>):<fpage>3848</fpage>&#x2013;<lpage>3860</lpage>.</mixed-citation></ref>
<ref id="c63"><mixed-citation publication-type="journal"><string-name><surname>Ribeiro</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Qin</surname> <given-names>L</given-names></string-name>, <string-name><surname>Chavez</surname> <given-names>LL</given-names></string-name>, <string-name><surname>Li</surname> <given-names>D</given-names></string-name>, <string-name><surname>Self</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Perelson</surname> <given-names>AS</given-names></string-name>. <article-title>Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection</article-title>. <source>Journal of virology</source>. <year>2010</year>; <volume>84</volume>(<issue>12</issue>):<fpage>6096</fpage>&#x2013;<lpage>6102</lpage>.</mixed-citation></ref>
<ref id="c64"><mixed-citation publication-type="journal"><string-name><surname>Rudnicka</surname> <given-names>D</given-names></string-name>, <string-name><surname>Feldmann</surname> <given-names>J</given-names></string-name>, <string-name><surname>Porrot</surname> <given-names>F</given-names></string-name>, <string-name><surname>Wietgrefe</surname> <given-names>S</given-names></string-name>, <string-name><surname>Guadagnini</surname> <given-names>S</given-names></string-name>, <string-name><surname>Pr&#x00E9;vost</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Estaquier</surname> <given-names>J</given-names></string-name>, <string-name><surname>Haase</surname> <given-names>AT</given-names></string-name>, <string-name><surname>Sol-Foulon</surname> <given-names>N</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>O</given-names></string-name>. <article-title>Simultaneous cell-to-cell transmission of human immunodefficiency virus to multiple targets through polysynapses</article-title>. <source>Journal of virology</source>. <year>2009</year>; <volume>83</volume>(<issue>12</issue>):<fpage>6234</fpage>&#x2013;<lpage>6246</lpage>.</mixed-citation></ref>
<ref id="c65"><mixed-citation publication-type="journal"><string-name><surname>Saenz</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Bonhoeffer</surname> <given-names>S</given-names></string-name>. <article-title>Nested model reveals potential amplification of an HIV epidemic due to drug resistance</article-title>. <source>Epidemics</source>. <year>2013</year>; <volume>5</volume>(<issue>1</issue>):<fpage>34</fpage>&#x2013;<lpage>43</lpage>.</mixed-citation></ref>
<ref id="c66"><mixed-citation publication-type="journal"><string-name><surname>Sherer</surname> <given-names>NM</given-names></string-name>, <string-name><surname>Lehmann</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Jimenez-Soto</surname> <given-names>LF</given-names></string-name>, <string-name><surname>Horensavitz</surname> <given-names>C</given-names></string-name>, <string-name><surname>Pypaert</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mothes</surname> <given-names>W</given-names></string-name>. <article-title>Retroviruses can establish 1lopodial bridges for efficient cell-to-cell transmission</article-title>. <source>Nature cell biology</source>. <year>2007</year>; <volume>9</volume>(<issue>3</issue>):<fpage>310</fpage>.</mixed-citation></ref>
<ref id="c67"><mixed-citation publication-type="journal"><string-name><surname>Sigal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Baltimore</surname> <given-names>D</given-names></string-name>. <article-title>As good as it gets? The problem of HIV persistence despite antiretroviral drugs</article-title>. <source>Cell host &#x0026; microbe</source>. <year>2012</year>; <volume>12</volume>(<issue>2</issue>):<fpage>132</fpage>&#x2013;<lpage>138</lpage>.</mixed-citation></ref>
<ref id="c68"><mixed-citation publication-type="journal"><string-name><surname>Sigal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Balazs</surname> <given-names>AB</given-names></string-name>, <string-name><surname>Dekel</surname> <given-names>E</given-names></string-name>, <string-name><surname>Mayo</surname> <given-names>A</given-names></string-name>, <string-name><surname>Milo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Baltimore</surname> <given-names>D</given-names></string-name>. <article-title>Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy</article-title>. <source>Nature</source>. <year>2011</year>; <volume>477</volume>(<issue>7362</issue>):<fpage>95</fpage>.</mixed-citation></ref>
<ref id="c69"><mixed-citation publication-type="journal"><string-name><surname>Siliciano</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Kajdas</surname> <given-names>J</given-names></string-name>, <string-name><surname>Finzi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Quinn</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Chadwick</surname> <given-names>K</given-names></string-name>, <string-name><surname>Margolick</surname> <given-names>JB</given-names></string-name>, <string-name><surname>Kovacs</surname> <given-names>C</given-names></string-name>, <string-name><surname>Gange</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Siliciano</surname> <given-names>RF</given-names></string-name>. <article-title>Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4&#x002B; T cells</article-title>. <source>Nature medicine</source>. <year>2003</year>; <volume>9</volume>(<issue>6</issue>):<fpage>727</fpage>.</mixed-citation></ref>
<ref id="c70"><mixed-citation publication-type="journal"><string-name><surname>Sowinski</surname> <given-names>S</given-names></string-name>, <string-name><surname>Jolly</surname> <given-names>C</given-names></string-name>, <string-name><surname>Berninghausen</surname> <given-names>O</given-names></string-name>, <string-name><surname>Purbhoo</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Chauveau</surname> <given-names>A</given-names></string-name>, <string-name><surname>K&#x00F6;hler</surname> <given-names>K</given-names></string-name>, <string-name><surname>Oddos</surname> <given-names>S</given-names></string-name>, <string-name><surname>Eissmann</surname> <given-names>P</given-names></string-name>, <string-name><surname>Brodsky</surname> <given-names>FM</given-names></string-name>, <string-name><surname>Hopkins</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission</article-title>. <source>Nature cell biology</source>. <year>2008</year>; <volume>10</volume>(<issue>2</issue>):<fpage>211</fpage>.</mixed-citation></ref>
<ref id="c71"><mixed-citation publication-type="journal"><string-name><surname>Spinner</surname> <given-names>CD</given-names></string-name>, <string-name><surname>Boesecke</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zink</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jessen</surname> <given-names>H</given-names></string-name>, <string-name><surname>Stellbrink</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Rockstroh</surname> <given-names>JK</given-names></string-name>, <string-name><surname>Esser</surname> <given-names>S</given-names></string-name>. <article-title>HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans</article-title>. <source>Infection</source>. <year>2016</year>; <volume>44</volume>(<issue>2</issue>):<fpage>151</fpage>&#x2013;<lpage>158</lpage>.</mixed-citation></ref>
<ref id="c72"><mixed-citation publication-type="journal"><string-name><surname>Supervie</surname> <given-names>V</given-names></string-name>, <string-name><surname>Barrett</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kahn</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Musuka</surname> <given-names>G</given-names></string-name>, <string-name><surname>Moeti</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Busang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Blower</surname> <given-names>S</given-names></string-name>. <article-title>Modeling dynamic interactions between pre-exposure prophylaxis interventions &#x0026; treatment programs: predicting HIV transmission &#x0026; resistance</article-title>. <source>Scientific reports</source>. <year>2011</year>; <volume>1</volume>:<fpage>185</fpage>.</mixed-citation></ref>
<ref id="c73"><mixed-citation publication-type="journal"><string-name><surname>Supervie</surname> <given-names>V</given-names></string-name>, <string-name><surname>Garc&#x00ED;a-Lerma</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Heneine</surname> <given-names>W</given-names></string-name>, <string-name><surname>Blower</surname> <given-names>S</given-names></string-name>. <article-title>HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis</article-title>. <source>Proceedings of the National Academy of Sciences</source>. <year>2010</year>; <volume>107</volume>(<issue>27</issue>):<fpage>12381</fpage>&#x2013;<lpage>12386</lpage>.</mixed-citation></ref>
<ref id="c74"><mixed-citation publication-type="journal"><string-name><surname>Thigpen</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Kebaabetswe</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Paxton</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>DK</given-names></string-name>, <string-name><surname>Rose</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Segolodi</surname> <given-names>TM</given-names></string-name>, <string-name><surname>Henderson</surname> <given-names>FL</given-names></string-name>, <string-name><surname>Pathak</surname> <given-names>SR</given-names></string-name>, <string-name><surname>Soud</surname> <given-names>FA</given-names></string-name>, <string-name><given-names>Chillag R</given-names> <surname>Kata L Mutanhaurwa</surname></string-name>, <string-name><surname>Chirwa</surname> <given-names>LI</given-names></string-name>, <string-name><surname>Kasonde</surname> <given-names>M</given-names></string-name>, <string-name><surname>Abebe</surname> <given-names>D</given-names></string-name>, <string-name><surname>Buliva</surname> <given-names>E</given-names></string-name>, <string-name><surname>Gvetadze</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sukalac</surname> <given-names>T</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>VT</given-names></string-name>, <string-name><surname>Hart</surname> <given-names>C</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Malotte</surname> <given-names>CK</given-names></string-name>, <string-name><surname>Hendrix</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Brooks</surname> <given-names>JT</given-names></string-name>. <article-title>Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana</article-title>. <source>New England Journal of Medicine</source>. <year>2012</year>; <volume>367</volume>(<issue>5</issue>):<fpage>423</fpage>&#x2013;<lpage>434</lpage>.</mixed-citation></ref>
<ref id="c75"><mixed-citation publication-type="journal"><string-name><surname>Van Damme</surname> <given-names>L</given-names></string-name>, <string-name><surname>Corneli</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ahmed</surname> <given-names>K</given-names></string-name>, <string-name><surname>Agot</surname> <given-names>K</given-names></string-name>, <string-name><surname>Lombaard</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kapiga</surname> <given-names>S</given-names></string-name>, <string-name><surname>Malahleha</surname> <given-names>M</given-names></string-name>, <string-name><surname>Owino</surname> <given-names>F</given-names></string-name>, <string-name><surname>Manongi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Onyango</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Preexposure prophylaxis for HIV infection among African women</article-title>. <source>New England Journal of Medicine</source>. <year>2012</year>; <volume>367</volume>(<issue>5</issue>):<fpage>411</fpage>&#x2013;<lpage>422</lpage>.</mixed-citation></ref>
<ref id="c76"><mixed-citation publication-type="journal"><string-name><surname>Van De Vijver</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Nichols</surname> <given-names>BE</given-names></string-name>, <string-name><surname>Abbas</surname> <given-names>UL</given-names></string-name>, <string-name><surname>Boucher</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Cambiano</surname> <given-names>V</given-names></string-name>, <string-name><surname>Eaton</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Glaubius</surname> <given-names>R</given-names></string-name>, <string-name><surname>Lythgoe</surname> <given-names>K</given-names></string-name>, <string-name><surname>Mellors</surname> <given-names>J</given-names></string-name>, <string-name><surname>Phillips</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sigaloff</surname> <given-names>KC</given-names></string-name>, <string-name><surname>Hallett</surname> <given-names>TB</given-names></string-name>. <article-title>Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models</article-title>. <source>Aids</source>. <year>2013</year>; <volume>27</volume>(<issue>18</issue>):<fpage>2943</fpage>&#x2013;<lpage>2951</lpage>.</mixed-citation></ref>
<ref id="c77"><mixed-citation publication-type="book"><string-name><surname>Wagner</surname> <given-names>JG</given-names></string-name>. <source>Fundamentals of clinical pharmacokinetics</source>. <publisher-name>Drug Intelligence Publications</publisher-name>; <year>1975</year>.</mixed-citation></ref>
<ref id="c78"><mixed-citation publication-type="journal"><string-name><surname>Wei</surname> <given-names>X</given-names></string-name>, <string-name><surname>Decker</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Arani</surname> <given-names>RB</given-names></string-name>, <string-name><surname>Kilby</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Saag</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Shaw</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Kappes</surname> <given-names>JC</given-names></string-name>. <article-title>Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy</article-title>. <source>Antimicrobial agents and chemotherapy</source>. <year>2002</year>; <volume>46</volume>(<issue>6</issue>):<fpage>1896</fpage>&#x2013;<lpage>1905</lpage>.</mixed-citation></ref>
<ref id="c79"><mixed-citation publication-type="journal"><collab>WHO</collab>. <article-title>Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV, web supplement: annex 2: evidence to decision-making tables and supporting evidence</article-title>. <source>World Health Organization</source>; <year>2015</year>.</mixed-citation></ref>
<ref id="c80"><mixed-citation publication-type="journal"><string-name><surname>Wu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Beddall</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Marsh</surname> <given-names>JW</given-names></string-name>. <article-title>Rev-dependent indicator T cell line</article-title>. <source>Current HIV research</source>. <year>2007</year>; <volume>5</volume>(<issue>4</issue>):<fpage>394</fpage>&#x2013;<lpage>402</lpage>.</mixed-citation></ref>
<ref id="c81"><mixed-citation publication-type="journal"><string-name><surname>Zhong</surname> <given-names>P</given-names></string-name>, <string-name><surname>Agosto</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Ilinskaya</surname> <given-names>A</given-names></string-name>, <string-name><surname>Dorjbal</surname> <given-names>B</given-names></string-name>, <string-name><surname>Truong</surname> <given-names>R</given-names></string-name>, <string-name><surname>Derse</surname> <given-names>D</given-names></string-name>, <string-name><surname>Uchil</surname> <given-names>PD</given-names></string-name>, <string-name><surname>Heidecker</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mothes</surname> <given-names>W</given-names></string-name>. <article-title>Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV</article-title>. <source>PloS one</source>. <year>2013</year>; <volume>8</volume>(<issue>1</issue>):<fpage>e53138</fpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>